ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1.
Silgard, suspension for injection.
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed).
2.
1 dose (0.5 ml) contains approximately:
Human Papillomavirus
1
Type 6 L1 protein
2,3
20 micrograms
Human Papillomavirus
1
Type 11 L1 protein
2,3
40 micrograms
Human Papillomavirus
1
Type 16 L1 protein
2,3
40 micrograms
Human Papillomavirus
1
Type 18 L1 protein
2,3
20 micrograms.
1
Human Papillomavirus = HPV.
2
L1 protein in the form of virus-like particles produced in yeast cells (
Saccharomyces cerevisiae
CANADE 3C-5 (Strain 1895)) by recombinant DNA technology.
3
adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (225 micrograms Al).
For a full list of excipients, see section 6.1.
3.
Suspension for injection.
Prior to agitation, Silgard may appear as a clear liquid with a white precipitate. After thorough
agitation, it is a white, cloudy liquid.
4.
Silgard is a vaccine for use from the age of 9 years for the prevention of:
-
premalignant genital lesions (cervical, vulvar and vaginal) and cervical cancer causally related
to certain oncogenic Human Papillomavirus (HPV) types
-
external genital warts (condyloma acuminata) causally related to specific HPV types.
See sections 4.4 and 5.1 for important information on the data that support this indication.
The use of Silgard should be in accordance with official recommendations.
The primary vaccination series consists of 3 separate 0.5 ml doses administered according to the
following schedule: 0, 2, 6 months.
If an alternate vaccination schedule is necessary, the second dose should be administered at least one
month after the first dose and the third dose should be administered at least 3 months after the second
dose. All three doses should be given within a 1-year period.
The need for a booster dose has not been established
.
2
Paediatric population: There is no experience with the use of Silgard in children below 9 years of age
(see section 5.1).
The vaccine should be administered by intramuscular injection. The preferred site is the deltoid area of
the upper arm or in the higher anterolateral area of the thigh.
Silgard must not be injected intravascularly. Neither subcutaneous nor intradermal administration has
been studied.
These methods of administration are not recommended (see section 6.6).
It is recommended that individuals who receive a first dose of Silgard complete the 3-dose vaccination
course with Silgard (see section 4.4).
Hypersensitivity to the active substances or to any of the excipients.
Individuals who develop symptoms indicative of hypersensitivity after receiving a dose of Silgard
should not receive further doses of Silgard.
Administration of Silgard should be postponed in individuals suffering from an acute severe febrile
illness. However, the presence of a minor infection, such as a mild upper respiratory tract infection or
low-grade fever, is not a contraindication for immunisation.
The decision to vaccinate an individual woman should take into account her risk for previous HPV
exposure and her potential benefit from vaccination.
As with all injectable vaccines, appropriate medical treatment should always be readily available in
case of rare anaphylactic reactions following the administration of the vaccine.
Syncope (fainting) may follow any vaccination, especially in adolescents and young adults. Syncope,
sometimes associated with falling, has occurred after vaccination with Silgard (See section 4.8).
Therefore, vaccinees should be carefully observed for approximately 15 minutes after administration
of Silgard.
As with any vaccine, vaccination with Silgard may not result in protection in all vaccine recipients.
Silgard will only protect against diseases that are caused by HPV types 6, 11, 16 and 18 and to a
limited extent against diseases caused by certain related HPV types (See section 5.1). Therefore,
appropriate precautions against sexually transmitted diseases should continue to be used.
Silgard is for prophylactic use only and has no effect on active HPV infections or established clinical
disease. Silgard has not been shown to have a therapeutic effect. The vaccine is therefore not indicated
for treatment of cervical cancer, high-grade cervical, vulvar and vaginal dysplastic lesions or genital
warts. It is also not intended to prevent progression of other established HPV-related lesions.
Silgard does not prevent lesions due to a vaccine HPV type in women infected with that HPV type at
the time of vaccination (see section 5.1).
The use of Silgard in adult women should take into consideration the variability of HPV type
prevalence in different geographical areas. Vaccination is not a substitute for routine cervical
screening. Since no vaccine is 100% effective and Silgard will not provide protection against every
HPV type, or against existing HPV infections, routine cervical screening remains critically important
and should follow local recommendations.
3
There are no data on the use of Silgard in individuals with impaired immune responsiveness.
Individuals with impaired immune responsiveness, whether due to the use of potent
immunosuppressive therapy, a genetic defect, Human Immunodeficiency Virus (HIV) infection, or
other causes, may not respond to the vaccine.
This vaccine should be given with caution to individuals with thrombocytopaenia or any coagulation
disorder because bleeding may occur following an intramuscular administration in these individuals.
The duration of protection is currently unknown. Sustained protective efficacy has been observed for
4.5 years after completion of the 3-dose series. Longer term follow-up studies are ongoing (see section
5.1).
There are no safety, immunogenicity or efficacy data to support interchangeability of Silgard with
other HPV vaccines.
In all clinical trials, individuals who had received immunoglobulin or blood-derived products during
the 6 months prior to the first vaccine dose were excluded.
Use with other vaccines
Administration of Silgard at the same time (but, for injected vaccines, at a different injection site) as
hepatitis B (recombinant) vaccine did not interfere with the immune response to the HPV types. The
seroprotection rates (proportion of individuals reaching seroprotective level anti-HBs >10 mIU/ml)
were unaffected (96.5% for concomitant vaccination and 97.5% for hepatitis B vaccine only). Anti-
HBs geometric mean antibody titres were lower on co-administration, but the clinical significance of
this observation is not known.
Silgard may be administered concomitantly with a combined booster vaccine containing diphtheria (d)
and tetanus (T) with either pertussis [acellular, component] (ap) and/or poliomyelitis [inactivated]
(IPV) (dTap, dT-IPV, dTap-IPV vaccines) with no significant interference with antibody response to
any of the components of either vaccine. However, a trend of lower anti-HPV GMTs was observed in
the concomitant group. The clinical significance of this observation is not known. This is based on the
results from a clinical trial in which a combined dTap-IPV vaccine was administered concomitantly
with the first dose of Silgard. (see section 4.8).
The concomitant administration of Silgard with vaccines other than the ones above has not been
studied.
Use with hormonal contraceptives
In clinical studies, 57.5% of women aged 16 to 26 years and 31.2% of women aged 24 to 45 years
who received Silgard used hormonal contraceptives during the vaccination period. Use of hormonal
contraceptives did not appear to affect the immune response to Silgard.
Specific studies of the vaccine in pregnant women were not conducted. During the clinical
development program, 3,819 women (vaccine = 1,894 vs. placebo = 1,925) reported at least one
pregnancy. There were no significant differences in types of anomalies or proportion of pregnancies
with an adverse outcome in Silgard and placebo treated individuals.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy,
embryonal/foetal development, parturition or postnatal development (see section 5.3).
4
The data on Silgard administered during pregnancy did not indicate any safety signal. However, these
data are insufficient to recommend use of Silgard during pregnancy. Vaccination should, therefore, be
postponed until completion of pregnancy.
In breastfeeding mothers given Silgard or placebo during the vaccination period of the clinical trials
the rates of adverse reactions in the mother and the breastfed infant were comparable between the
vaccination and the placebo groups. In addition, vaccine immunogenicity was comparable among
breastfeeding mothers and women who did not breastfeed during the vaccine administration.
Therefore Silgard can be given to breastfeeding women.
No studies on the effects on the ability to drive and use machines have been performed.
In 6 clinical trials (5 placebo-controlled), individuals were administered Silgard or placebo on the day
of enrollment and approximately 2 and 6 months thereafter. Few individuals (0.2%) discontinued due
to adverse reactions. Safety was evaluated in either the entire study population (5 studies) or in a
predefined subset (one study) of the study population using vaccination report card (VRC)-aided
surveillance for 14 days after each injection of Silgard or placebo. The individuals who were
monitored using VRC-aided surveillance included 8,068 individuals (6,996 females 9 to 45 years of
age and 1,072 males 9 to 15 years of age at enrollment) who received Silgard and 5,966 individuals
who received placebo.
The following vaccine-related adverse reactions were observed among recipients of Silgard at a
frequency of at least 1.0% and also at a greater frequency than observed among placebo recipients.
They are ranked under headings of frequency using the following convention:
[Very Common (≥1/10); Common (≥1/100, <1/10); Uncommon (≥1/1,000, <1/100); Rare (≥1/10,000,
<1/1,000); Very Rare (<1/10,000), including isolated reports]
Musculoskeletal and Connective Tissue Disorders:
Common: pain in extremity.
General disorders and administration site conditions:
Very common: pyrexia.
Very common: at the injection site: erythema, pain, swelling.
Common: at the injection site: bruising, pruritus.
In addition, in clinical trials adverse reactions that were judged to be vaccine- or placebo-related by
the study investigator were observed at frequencies lower than 1%:
Respiratory, thoracic and mediastinal disorders:
Very rare: bronchospasm.
Skin and subcutaneous tissue disorder:
Rare: urticaria.
Nine cases (0.07%) of urticaria were reported in the Silgard group and 16 cases (0.14%) were seen in
the adjuvant-containing placebo group.
In the clinical studies, individuals in the Safety Population reported any new medical conditions
during the follow-up of up to 4 years. Among 13,686 individuals who received Silgard and 11,588
individuals who received placebo, there were 38 cases of non-specific arthritis/arthropathy reported,
5
24 in the Silgard group and 14 in the placebo group.
In a clinical trial of 843 healthy adolescent males and females 11-17 years of age, administration of the
first dose of Silgard concomitantly with a combined diphtheria, tetanus, pertussis [acellular,
component] and poliomyelitis [inactivated] booster vaccine showed that there was more injection-site
swelling and headache reported following concomitant administration. The differences observed were
< 10% and in the majority of subjects, the adverse events were reported as mild to moderate in
intensity.
Post Marketing Experience
Post Marketing adverse events have been spontaneously reported for Silgard and are not listed above.
Because these events were reported voluntarily from a population of uncertain size, it is not possible to
reliably estimate their frequency or to establish, for all events, a causal relationship to vaccine
exposure.
Blood and lymphatic system disorders
: idiopathic thrombocytopenic purpura, lymphadenopathy.
Immune system disorders
: hypersensitivity reactions including anaphylactic/anaphylactoid reactions.
Nervous system disorders
: Guillain-Barré syndrome, dizziness,
headache, syncope sometimes
accompanied by tonic-clonic movements.
Gastrointestinal disorders
: nausea, vomiting.
Musculoskeletal and connective tissue disorders
: arthralgia, myalgia.
General disorders and administration site conditions
: asthenia, chills, fatigue, malaise.
There have been reports of administration of higher than recommended doses of Silgard.
In general, the adverse event profile reported with overdose was comparable to recommended single
doses of Silgard.
5.
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Viral Vaccine, ATC code: J07BM01
Mechanism of Action
Silgard is an adjuvanted non-infectious recombinant quadrivalent vaccine prepared from the highly
purified virus-like particles (VLPs) of the major capsid L1 protein of HPV types 6, 11, 16 and 18. The
VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. HPV only infects
humans, but animal studies with analogous papillomaviruses suggest that the efficacy of LI VLP
vaccines is mediated by the development of a humoral immune response.
HPV 16 and HPV 18 are estimated to be responsible for approximately 70% of cervical cancers; 80%
of adenocarcinoma in situ (AIS); 45-70% of high-grade cervical intraepithelial neoplasia (CIN 2/3);
25% of low grade cervical intraepithelial neoplasia (CIN 1); approximately 70% of HPV related high-
grade vulvar (VIN 2/3) and vaginal (VaIN 2/3) intraepithelial neoplasia. HPV 6 and 11 are responsible
6
for approximately 90% of genital warts and 10% of low grade cervical intraepithelial neoplasia (CIN
1). CIN 3 and AIS have been accepted as immediate precursors of invasive cervical cancer.
The term "premalignant genital lesions" in section 4.1 corresponds to high-grade cervical
intraepithelial neoplasia (CIN 2/3), high-grade vulvar intraepithelial neoplasia (VIN 2/3) and high-
grade vaginal intraepithelial neoplasia (VaIN 2/3).
The indication is based on the demonstration of efficacy of Silgard in females 16 to 45 years of age
and on the demonstration of immunogenicity of Silgard in 9- to 15-year old children and adolescents.
Clinical Studies
Efficacy in women 16 through 26 years
The efficacy of Silgard in 16- through 26- year-old women was assessed in 4 placebo-controlled,
double-blind, randomized Phase II and III clinical studies including a total of 20,541 women, who
were enrolled and vaccinated without pre-screening for the presence of HPV infection.
The primary efficacy endpoints included HPV 6-, 11-, 16-, or 18-related vulvar and vaginal lesions
(genital warts, VIN, VaIN) and CIN of any grade and cervical cancers (Protocol 013, FUTURE I),
HPV 16- or 18-related CIN 2/3 and AIS and cervical cancers (Protocol 015, FUTURE II), HPV 6-, 11-
, 16-, or 18-related persistent infection and disease (Protocol 007), and HPV 16-related persistent
infection (Protocol 005).
Efficacy results are presented for the combined analysis of study protocols. The efficacy for HPV
16/18 related CIN 2/3 or AIS is based on data from protocols 005 (16-related endpoints only), 007,
013, and 015. The efficacy for all other endpoints is based on protocols 007, 013, and 015. The median
duration of follow-up for these studies was 4.0, 3.0, 3.0, and 3.0 years for Protocol 005, Protocol 007,
Protocol 013, and Protocol 015, respectively. The median duration of follow-up for the combined
protocols (005, 007, 013, and 015) was 3.6 years. Results of individual studies support the results from
the combined analysis. Silgard was efficacious against HPV disease caused by each of the four
vaccine HPV types. At end of study, individuals enrolled in the two Phase-III studies (Protocol-013
and Protocol-015), were followed for up to 4 years (median 3.7 years).
Cervical Intraepithelial Neoplasia (CIN) Grade 2/3 (moderate to high-grade dysplasia) and
adenocarcinoma in situ
(AIS) were used in the clinical trials as a surrogate marker for cervical cancer.
Efficacy in women naïve to the relevant vaccine HPV type(s)
The primary analyses of efficacy, with respect to vaccine HPV types (HPV 6, 11, 16, and 18), were
conducted in the per-protocol efficacy (PPE) population (i.e. all 3 vaccinations within 1 year of
enrollment, no major protocol deviations and naïve to the relevant HPV type(s) prior to dose 1 and
through 1 month Postdose 3 (Month 7)). Efficacy was measured starting after the Month 7 visit.
Overall, 73% of women were naïve (PCR negative and seronegative) to all 4 HPV types at enrollment.
The efficacy results for relevant endpoints analysed at 2 years post-enrollment and at end of study
(median duration of follow-up = 3.6 years) in the per-protocol population are presented in the Table 1.
In a supplemental analysis, the efficacy of Silgard was evaluated against HPV 16/18-related CIN 3 and
AIS.
7
Table 1: Analysis of efficacy of Silgard against high grade cervical lesions in the PPE population
Silgard
Placebo
%
Efficacy
at 2
years
(95%
CI)
Silgard
Placebo
%
Efficacy***
at end of
study
(95% CI)
Number of
cases
Number of
individuals*
Number of
cases
Number of
individuals*
Number of
cases
Number of
individuals*
Number of
cases
Number of
individuals*
HPV 16/18-
related CIN
2/3 or AIS
0
8487
53
8460
100.0
(92.9,
100.0)
2**
8493
112
8464
98.2
(93.5, 99.8)
HPV 16/18-
related CIN 3
0
8487
29
8460
100
(86.5,
100.0)
2**
8493
64
8464
96.9
(88.4, 99.6)
HPV 16/18-
related AIS
0
8487
6
8460
100
(14.8,
100.0)
0
8493
7
8464
100
(30.6,
100.0)
*Number of individuals with at least one follow-up visit after Month 7
**
Based on virologic evidence, the first CIN 3 case in a patient chronically infected with HPV 52 is
likely to be causally related to HPV 52. In only 1 of 11 specimens HPV 16 was found (at Month 32.5)
and was not detected in tissue excised during LEEP (Loop Electro-Excision Procedure). In the second
CIN 3 case observed in a patient infected with HPV 51 at Day 1 (in 2 of 9 specimens); HPV 16 was
detected at a Month 51 biopsy (in 1 of 9 specimens) and HPV 56 was detected in 3 of 9 specimens at
Month 52 in tissue excised during LEEP.
***Patients were followed for up to 4 years (median 3.6 years)
Note: Point estimates and confidence intervals are adjusted for person-time of follow-up.
At end of study and in the combined protocols,
the efficacy of Silgard against HPV 6-, 11-, 16-, 18-related CIN 1 was 95.9 % (95% CI: 91.4, 98.4)
the efficacy of Silgard against HPV 6-, 11-, 16-, 18-related CIN (1, 2, 3) or AIS was 96.0% (95% CI:
92.3, 98.2)
the efficacy of Silgard against HPV 6-, 11-, 16-, 18-related VIN2/3 and VaIN 2/3 was 100% (95% CI:
67.2, 100) and 100% (95% CI: 55.4, 100) respectively
the efficacy of Silgard against HPV 6-, 11-, 16-, 18-related genital warts was 99.0% (95% CI: 96.2,
99.9).
In Protocol 012 the efficacy of Silgard against the 6 month definition of persistent infection [samples
positive on two or more consecutive visits 6 months apart (±1 month) or longer] related to HPV 16
was 98.7 % (95% CI: 95.1, 99.8) and 100.0% (95% CI: 93.2, 100.0) for HPV 18 respectively, after a
follow-up of up to 4 years (mean of 3.6 years). For the 12 month definition of persistent infection,
efficacy against HPV 16 was 100.0 % (95% CI: 93.9, 100.0) and 100.0 % (95% CI: 79.9, 100.0) for
HPV 18 respectively
.
Efficacy in women with evidence of HPV 6, 11, 16, or 18 infection or disease at day 1
There was no evidence of protection from disease caused by vaccine HPV types for which women
were PCR positive at day 1. Women who were already infected with one or more vaccine-related HPV
types prior to vaccination were protected from clinical disease caused by the remaining vaccine HPV
types.
Efficacy in women with and without prior infection or disease due to HPV 6, 11, 16, or 18
The modified intention to treat (ITT) population included women regardless of baseline HPV status at
Day 1, who received at least one vaccination and in whom case counting started at 1 month Postdose
1. This population approximates to the general population of women with respect to prevalence of
HPV infection
or disease at enrollment. The results are summarised in Table 2.
8
Table 2: Efficacy of Silgard in high grade cervical lesions in the modified ITT-population including
women regardless of baseline HPV status
Silgard
Placebo
%
Efficacy**
at 2 years
(95% CI)
Silgard
Placebo
%
Efficacy**
at end of
study
(95% CI)
Number of
cases
Number of
individuals*
Number of
cases
Number of
individuals*
Number of
cases
Number of
individuals*
Number of
cases
Number of
individuals*
HPV 16- or
HPV 18-
related CIN
2/3 or AIS
122
9831
201
9896
39.0
(23.3,
51.7)
146
9836
303
9904
51.8
(41.1,
60.7)
HPV 16/18-
related CIN
3
83
9831
127
9896
34.3
(12.7,
50.8)
103
9836
191
9904
46.0
(31.0,
57.9)
HPV 16/18-
related AIS
5
9831
11
9896
54.3
(<0, 87.6)
6
9836
15
9904
60.0
(<0, 87.3)
*Number of individuals with at least one follow-up visit after 30 days after Day 1
**Percent efficacy is calculated from the combined protocols. The efficacy for HPV 16/18 related CIN
2/3 or AIS is based on data from protocols 005 (16-related endpoints only), 007, 013, and 015.
Patients were followed for up to 4 years (median 3.6 years).
Note: point estimates and confidence intervals are adjusted for person-time of follow-up.
Efficacy against HPV 6-, 11-, 16-, 18-related VIN 2/3 was 73.3% (95% CI: 40.3, 89.4), against HPV
6-, 11-, 16-, 18-related VaIN 2/3 was 85.7% (95% CI: 37.6, 98.4), and against HPV 6-, 11-, 16-, 18-
related genital warts was 80.3% (95% CI: 73.9, 85.3) in the combined protocols at end of study.
Overall 12% of the combined study population had an abnormal Pap test suggestive of CIN at Day 1.
Among women with an abnormal Pap test at Day 1 who were naïve to the relevant vaccine HPV types
at Day 1, efficacy of the vaccine remained high. Among women with an abnormal Pap test at Day 1
who were already infected with the relevant vaccine HPV types at Day 1, no vaccine efficacy was
observed.
Protection Against the Overall Burden of Cervical HPV disease in 16- Through 26-Year-Old Women
The impact of Silgard against the overall risk for cervical, HPV disease (i.e., disease caused by any
HPV type) was evaluated starting 30 days after the first dose in 17,599 individuals enrolled in the two
phase III efficacy trials (Protocols 013 and 015). Among women who were naïve to 14 common HPV
types and had a negative Pap test at Day 1, administration of Silgard reduced the incidence of CIN 2/3
or AIS caused by vaccine- or non-vaccine HPV types by 42.7% (95% CI: 23.7, 57.3) and of genital
warts by 82.8% (95% CI: 74.3, 88.8) at end of study.
In the modified ITT population, the benefit of the vaccine with respect to the overall incidence of CIN
2/3 or AIS (caused by any HPV type) and of genital warts was much lower, with a reduction of 18.4%
(95% CI: 7.0, 28.4) and 62.5% (95% CI: 54.0, 69.5), respectively, as Silgard does not impact the
course of infections or disease that are present at vaccination onset.
Impact on Definitive Cervical Therapy Procedures
The impact of Silgard on rates of Definitive Cervical Therapy Procedures regardless of causal HPV
types was evaluated in 18,150 individuals enrolled in Protocol 007, Protocols 013 and 015. In the HPV
naïve population (naïve to 14 common HPV types and had a negative Pap test at Day 1), Silgard
reduced the proportion of women who experienced a definitive cervical therapy procedure (Loop
Electro-Excision Procedure or Cold-Knife Conization) by 41.9% (95% CI: 27.7, 53.5) at end of study.
In the ITT population the corresponding reduction was 23.9% (95% CI: 15.2, 31.7).
9
Cross-protective efficacy
The efficacy of Silgard against CIN (any grade) and CIN 2/3 or AIS caused by 10 non-vaccine HPV
types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) structurally related to HPV 16 or HPV 18 was
evaluated in the combined Phase III efficacy database (N = 17,599) after a median follow-up of 3.7
years (at end of study). Efficacy against disease endpoints caused by pre-specified combinations of
non-vaccine HPV types was measured. The studies were not powered to assess efficacy against
disease caused by individual HPV types.
The primary analysis was done in type-specific populations that required women to be negative for the
type being analyzed, but who could be positive for other HPV types (96% of the overall population).
The primary time point analysis after 3 years did not reach statistical significance for all pre-specified
endpoints. The final end-of-study results for the combined incidence of CIN 2/3 or AIS in this
population after a median follow-up of 3.7 years are shown in Table 3. For composite endpoints,
statistically significant efficacy against disease was demonstrated against HPV types phylogenetically
related to HPV 16 (primarily HPV 31) whereas no statistically significant efficacy was observed for
HPV types phylogenetically related to HPV 18 (including HPV 45). For the 10 individual HPV types,
statistical significance was only reached for HPV 31.
Table 3: Results for CIN 2/3 or AIS in Type-Specific HPV-Naïve Individuals
†
(end of study resu
lts)
Naïve to ≥ 1 HPV Type
Silgard
Placebo
Composite Endpoint
cases
cases
% Efficacy
95% CI
(HPV 31/45)
‡
34
60
43.2%
12.1, 63.9
(HPV 31/33/45/52/58)
§
111
150
25.8%
4.6, 42.5
10 non-vaccine HPV
Types
║
162
211
23.0%
5.1, 37.7
HPV-16 related types
(A9 species)
111
157
29.1%
9.1, 44.9
HPV 31
23
52
55.6%
26.2, 74.1
†
HPV 33
29
36
19.1%
<0, 52.1
†
HPV 35
13
15
13.0%
<0, 61.9
†
HPV 52
44
52
14.7%
<0, 44.2
†
HPV 58
24
35
31.5%
<0, 61.0
†
HPV-18 related types
(A7 species)
34
46
25.9%
<0, 53.9
HPV 39 15 24 37.5% <0, 69.5
†
HPV 45 11 11 0.0% <0, 60.7
†
HPV 59 9 15 39.9% <0, 76.8
†
A5 species (HPV 51) 34 41 16.3% <0, 48.5
†
A6 species (HPV 56) 34 30 -13.7% <0, 32.5
†
†
The studies were not powered to assess efficacy against disease caused by individual HPV
types.
‡
Efficacy was based on reductions in HPV 31-related CIN 2/3 or AIS
§
Efficacy was based on reductions in HPV 31-, 33-, 52-, and 58-related CIN 2/3 or AIS
║
Includes assay-identified non-vaccine HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59.
Efficacy in women 24 through 45 years
The efficacy of Silgard in 24- through 45-year-old women was assessed in 1 placebo-controlled,
double-blind, randomized Phase III clinical study (Protocol 019, FUTURE III) including a total of
3,817 women, who were enrolled and vaccinated without pre-screening for the presence of HPV
infection.
10
The primary efficacy endpoints included the combined incidence of HPV 6-, 11-, 16- or 18-related and
the combined incidence of HPV 16- or HPV 18-related persistent infection (6 month definition),
genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers. The median
duration of follow-up for this study was 4.0 years.
Efficacy in women naïve to the relevant vaccine HPV type(s)
The primary analyses of efficacy were conducted in the per-protocol efficacy (PPE) population (i.e. all
3 vaccinations within 1 year of enrollment, no major protocol deviations and naïve to the relevant
HPV type(s) prior to dose 1 and through 1 month Postdose 3 (Month 7)). Efficacy was measured
starting after the Month 7 visit. Overall, 67% of individuals were naïve (PCR negative and
seronegative) to all 4 HPV types at enrollment.
The efficacy of Silgard against the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent
infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was
88.7% (95% CI: 78.1, 94.8).
The efficacy of Silgard against the combined incidence of HPV 16- or 18-related persistent infection,
genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 84.7%
(95% CI: 67.5, 93.7).
Efficacy in women with and without prior infection or disease due to HPV 6, 11, 16, or 18
The Full Analysis Set population (also known as the ITT population) included women regardless of
baseline HPV status at Day 1, who received at least one vaccination and in whom case counting
started at Day 1. This population approximates to the general population of women with respect to
prevalence of HPV infection or disease at enrollment.
The efficacy of Silgard against the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent
infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was
47.2% (95% CI: 33.5, 58.2).
The efficacy of Silgard against the combined incidence of HPV 16- or 18-related persistent infection,
genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 41.6%
(95% CI: 24.3, 55.2).
Efficacy in women (16 to 45 years) with evidence of a prior infection with a vaccine HPV type
(seropositive) that was no longer detectable at vaccination onset (PCR negative)
In post hoc analyses of individuals (who received at least one vaccination) with evidence of a prior
infection with a vaccine HPV type (seropositive) no longer detectable (PCR negative) at vaccination
onset, the efficacy of Silgard to prevent conditions due to the recurrence of the same HPV type was
100% (95% CI: 62.8, 100.0; 0 vs. 12 cases [n = 2572 from studies in young women]) against HPV 6-,
11-, 16-, and 18-related CIN 2/3, VIN 2/3, VaIN 2/3, and genital warts in women 16 to 26 years.
Efficacy was 68.2% (95% CI: 17.9, 89.5; 6 vs. 20 cases [n= 832 from studies in young and adult
women combined]) against HPV 16- and 18-related persistent infection in women 16 to 45 years.
Immunogenicity
Assays to Measure Immune Response
No minimum antibody level associated with protection has been identified for HPV vaccines.
The immunogenicity of Silgard was assessed in 20,132 (Silgard n = 10,723; placebo n = 9,409) girls
and women 9 to 26 years of age, 1,346 (Silgard n = 1,071; placebo n = 275) boys 9 to 15 years of age
and 3,819 women 24 to 45 years of age (Silgard n = 1,911, placebo n = 1,908).
11
Type-specific immunoassays, competitive Luminex-based immunoassay (cLIA), with type-specific
standards were used to assess immunogenicity to each vaccine type. This assay measures antibodies
against a single neutralizing epitope for each individual HPV type.
Immune Responses to Silgard at 1 month post dose 3
In the clinical studies in women 16 to 26 years of age,
99.8%, 99.8%, 99.8%, and 99.5% of individuals
who received Silgard became anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18-seropositive,
respectively, by 1 month Postdose 3. In the clinical study in women
24 to 45 years, 98.4%, 98.1%,
98.8%, and 97.4% of individuals who received Silgard became anti-HPV 6, anti-HPV 11, anti-HPV
16, and anti-HPV 18 seropositive, respectively, by 1 month Postdose 3. Silgard induced high anti-HPV
Geometric Mean Titres (GMTs) 1 month Postdose 3 in all age groups tested.
As expected for women 24 to 45 years of age (Protocol 019), the observed antibody titres were lower
than that seen in women 16 to 26 years.
Anti-HPV levels in placebo individuals who had cleared an HPV infection (seropositive and PCR
negative) were substantially lower than those induced by the vaccine. Furthermore, anti-HPV levels
(GMTs) in vaccinated individuals remained at or above serostatus cut-off during the long-term follow-
up of the phase III studies (see below under
Persistence of Immune Response of Silgard in Clinical
Studies
).
Bridging the Efficacy of Silgard from Young Adult Women to Young Adolescents
A clinical study (Protocol 016) compared the immunogenicity of Silgard in 10- to 15-year-old boys
and girls to those in 16- to 23-year old adolescent and young women. In the vaccine group, 99.1 to
100% became seropositive to all vaccine serotypes by 1 month Postdose 3
.
Table 4 compares the 1 month Postdose 3 anti-HPV 6, 11, 16, and 18 GMTs in 9- to 15-year-old boys
and girls with those in 16- to 26-year old young women.
Table 4: Immunogenicity bridging between 9- to 15-year-old male and female individuals and 16- to
26-year-old adult women (per-protocol population)
based on titres as measured by cLIA
9- to 15-Year-Old Males
(Protocols 016 and 018)
9- to 15-Year-Old Females
(Protocols 016 and 018)
16- to 26-Year-Old Females
(Protocols 013 and 015)
n
GMT (95% CI)
n
GMT (95% CI)
n
GMT (95% CI)
HPV 6 883
1038 (975, 1106)
915
929 (874, 987)
2631
543 (526, 560)
HPV 11 884
1387 (1299, 1481)
915
1303 (1223, 1388)
2655
762 (735, 789)
HPV 16 881
6053 (5599, 6543)
913
4909 (4548, 5300)
2570 2294 (2185, 2408)
HPV 18 886
1356 (1253, 1469)
920
1040 (965, 1120)
2796
462 (444, 480)
GMT- Geometric mean titre in mMU/ml (mMU = milli-Merck units)
Anti-HPV responses at Month 7 among 9- to 15-year-old girls and boys were non-inferior to anti-HPV
responses in 16- to 26-year-old young women for whom efficacy was established in the phase III
studies. Immunogenicity was related to age and Month 7 anti-HPV levels were significantly higher in
younger individuals below 12 years of age than in those above that age.
On the basis of this immunogenicity bridging, the efficacy of Silgard in 9- to 15-year-old girls is
inferred.
Immunogenicity and safety of Silgard have been demonstrated in 9- to 15-year-old boys. Protective
efficacy has not been evaluated in males.
12
Persistence of Immune Response of Silgard in Clinical Studies
In women 16-26 years of age, the longest follow-up of immunogenicity was in Protocol 007 where
peak anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 GMTs were observed at Month 7. The
GMTs declined through Month 24 and then stabilized until at least Month 60. The exact duration of
immunity following a 3-dose series has not been established.
In phase III studies in women 16 through 26 years,
at end of study, 90%, 95%, 98% and 60% of
individuals who received Silgard in the per-protocol immunogenicity population were anti-HPV 6,
anti-HPV 11, anti-HPV 16 and anti HPV 18 seropositive in the cLIA, respectively.
In the Phase III study in women 24 through 45 years, after a median follow-up of 4.0 years, 91.5 %,
92.0 %, 97.4 % and 47.9 % of individuals who received Silgard in the per-protocol immunogenicity
population were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the cLIA,
respectively.
In the longer term follow-up in women 16 to 45 years, individuals who were seronegative for anti-
HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 in the cLIA, at end of study, were still protected
against clinical disease.
Evidence of Anamnestic (Immune Memory) Response
Evidence of an anamnestic response was seen in vaccinated women who were seropositive to relevant
HPV type(s) prior to vaccination. In addition, a subset of vaccinated women who received a challenge
dose of Silgard 5 years after the onset of vaccination, exhibited a rapid and strong anamnestic response
that exceeded the anti-HPV GMTs observed 1 month Postdose 3.
5.2 Pharmacokinetic properties
Evaluation of pharmacokinetic studies is not required for vaccines.
5.3 Preclinical safety data
Single-dose and repeated-dose toxicity and local tolerance studies revealed no special hazards to
humans.
Silgard induced specific antibody responses against HPV types 6, 11, 16, and 18 in pregnant rats,
following one or multiple intramuscular injections. Antibodies against all four HPV types were
transferred to the offspring during gestation and possibly during lactation. There were no treatment-
related effects on developmental signs, behaviour, reproductive performance, or fertility of the
offspring.
6.
6.1 List of excipients
Sodium chloride
L-histidine
Polysorbate 80
Sodium borate
Water for injections
For adjuvant, see section 2.
6.2 Incompatibilities
13
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal
products.
6.3 Shelf life
3 years.
6.4 Special precautions for storage
Store in a refrigerator (2°C - 8°C).
Do not freeze. Keep the vial in the outer carton in order to protect from light.
6.5 Nature and contents of container
0.5 ml suspension in a vial (Type 1 glass) with stopper (FluroTec-coated or Teflon-coated chlorobutyl
elastomer) and flip-off plastic cap (aluminium crimp band) in a pack size of 1, 10 or 20.
Not all pack sizes are marketed.
6.6 Special precautions for disposal and other handling
The vaccine should be used as supplied; no dilution or reconstitution is necessary. The full
recommended dose of the vaccine should be used.
Shake well before use.
Thorough agitation immediately before administration is necessary to maintain
suspension of the vaccine.
Parenteral drug products should be inspected visually for particulate matter and discolouration prior to
administration. Discard the product if particulates are present or if it appears discoloured.
Single-dose Vial Use
Withdraw the 0.5 ml dose of vaccine from the single-dose vial using a sterile needle and syringe free
of preservatives, antiseptics, and detergents. Once the single-dose vial has been penetrated, the
withdrawn vaccine should be used promptly, and the vial must be discarded.
Disposal
Any unused product or waste material should be disposed of in accordance with local requirements.
7.
Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom
8.
EU/1/06/358/001
EU/1/06/358/002
EU/1/06/358/018
9.
14
20th September 2006
Detailed information on this product is available on the website of the European Medicines Agency
http://www.ema.europa.eu
15
1.
Silgard, suspension for injection in a pre-filled syringe.
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed).
2.
1 dose (0.5 ml) contains approximately:
Human Papillomavirus
1
Type 6 L1 protein
2,3
20 micrograms
Human Papillomavirus
1
Type 11 L1 protein
2,3
40 micrograms
Human Papillomavirus
1
Type 16 L1 protein
2,3
40 micrograms
Human Papillomavirus
1
Type 18 L1 protein
2,3
20 micrograms.
1
Human Papillomavirus = HPV.
2
L1 protein in the form of virus-like particles produced in yeast cells (
Saccharomyces cerevisiae
CANADE 3C-5 (Strain 1895)) by recombinant DNA technology.
3
adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (225 micrograms Al).
For a full list of excipients, see section 6.1.
3.
Suspension for injection in a pre-filled syringe.
Prior to agitation, Silgard may appear as a clear liquid with a white precipitate. After thorough
agitation, it is a white, cloudy liquid.
4.
Silgard is a vaccine for use from the age of 9 years for the prevention of:
-
premalignant genital lesions (cervical, vulvar and vaginal) and cervical cancer causally related
to certain oncogenic Human Papillomavirus (HPV) types
-
external genital warts (condyloma acuminata) causally related to specific HPV types.
See sections 4.4 and 5.1 for important information on the data that support this indication.
The use of Silgard should be in accordance with official recommendations.
The primary vaccination series consists of 3 separate 0.5 ml doses administered according to the
following schedule: 0, 2, 6 months.
If an alternate vaccination schedule is necessary, the second dose should be administered at least one
month after the first dose and the third dose should be administered at least 3 months after the second
dose. All three doses should be given within a 1-year period.
The need for a booster dose has not been established
.
16
Paediatric population: There is no experience with the use of Silgard in children below 9 years of age
(see section 5.1).
The vaccine should be administered by intramuscular injection. The preferred site is the deltoid area of
the upper arm or in the higher anterolateral area of the thigh.
Silgard must not be injected intravascularly. Neither subcutaneous nor intradermal administration has
been studied.
These methods of administration are not recommended (see section 6.6).
It is recommended that individuals who receive a first dose of Silgard complete the 3-dose vaccination
course with Silgard (see section 4.4).
Hypersensitivity to the active substances or to any of the excipients.
Individuals who develop symptoms indicative of hypersensitivity after receiving a dose of Silgard
should not receive further doses of Silgard.
Administration of Silgard should be postponed in individuals suffering from an acute severe febrile
illness. However, the presence of a minor infection, such as a mild upper respiratory tract infection or
low-grade fever, is not a contraindication for immunisation.
The decision to vaccinate an individual woman should take into account her risk for previous HPV
exposure and her potential benefit from vaccination.
As with all injectable vaccines, appropriate medical treatment should always be readily available in
case of rare anaphylactic reactions following the administration of the vaccine.
Syncope (fainting) may follow any vaccination, especially in adolescents and young adults. Syncope,
sometimes associated with falling, has occurred after vaccination with Silgard (See section 4.8).
Therefore, vaccinees should be carefully observed for approximately 15 minutes after administration
of Silgard.
As with any vaccine, vaccination with Silgard may not result in protection in all vaccine recipients.
Silgard will only protect against diseases that are caused by HPV types 6, 11, 16 and 18 and to a
limited extent against diseases caused by certain related HPV types (See section 5.1). Therefore,
appropriate precautions against sexually transmitted diseases should continue to be used.
Silgard is for prophylactic use only and has no effect on active HPV infections or established clinical
disease. Silgard has not been shown to have a therapeutic effect. The vaccine is therefore not indicated
for treatment of cervical cancer, high-grade cervical, vulvar and vaginal dysplastic lesions or genital
warts. It is also not intended to prevent progression of other established HPV-related lesions.
Silgard does not prevent lesions due to a vaccine HPV type in women infected with that HPV type at
the time of vaccination (see section 5.1).
The use of Silgard in adult women should take into consideration the variability of HPV type
prevalence in different geographical areas.Vaccination is not a substitute for routine cervical
screening. Since no vaccine is 100% effective and Silgard will not provide protection against every
HPV type, or against existing HPV infections, routine cervical screening remains critically important
and should follow local recommendations.
17
There are no data on the use of Silgard in individuals with impaired immune responsiveness.
Individuals with impaired immune responsiveness, whether due to the use of potent
immunosuppressive therapy, a genetic defect, Human Immunodeficiency Virus (HIV) infection, or
other causes, may not respond to the vaccine.
This vaccine should be given with caution to individuals with thrombocytopaenia or any coagulation
disorder because bleeding may occur following an intramuscular administration in these individuals.
The duration of protection is currently unknown. Sustained protective efficacy has been observed for
4.5 years after completion of the 3-dose series. Longer term follow-up studies are ongoing (see section
5.1).
There are no safety, immunogenicity or efficacy data to support interchangeability of Silgard with
other HPV vaccines.
In all clinical trials, individuals who had received immunoglobulin or blood-derived products during
the 6 months prior to the first vaccine dose were excluded.
Use with other vaccines
Administration of Silgard at the same time (but, for injected vaccines, at a different injection site) as
hepatitis B (recombinant) vaccine did not interfere with the immune response to the HPV types. The
seroprotection rates (proportion of individuals reaching seroprotective level anti-HBs >10 mIU/ml)
were unaffected (96.5% for concomitant vaccination and 97.5% for hepatitis B vaccine only). Anti-
HBs geometric mean antibody titres were lower on co-administration, but the clinical significance of
this observation is not known.
Silgard may be administered concomitantly with a combined booster vaccine containing diphtheria (d)
and tetanus (T) with either pertussis [acellular, component] (ap) and/or poliomyelitis [inactivated]
(IPV) (dTap, dT-IPV, dTap-IPV vaccines) with no significant interference with antibody response to
any of the components of either vaccine. However, a trend of lower anti-HPV GMTs was observed in
the concomitant group. The clinical significance of this observation is not known. This is based on the
results from a clinical trial in which a combined dTap-IPV vaccine was administered concomitantly
with the first dose of Silgard. (see section 4.8).
The concomitant administration of Silgard with vaccines other than the ones above has not been
studied.
Use with hormonal contraceptives
In clinical studies, 57.5% of women aged 16 to 26 years and 31.2% of women aged 24 to 45 years
who received Silgard used hormonal contraceptives during the vaccination period. Use of hormonal
contraceptives did not appear to affect the immune response to Silgard.
Specific studies of the vaccine in pregnant women were not conducted. During the clinical
development program, 3,819 women (vaccine = 1,894 vs. placebo = 1,925) reported at least one
pregnancy. There were no significant differences in types of anomalies or proportion of pregnancies
with an adverse outcome in Silgard and placebo treated individuals.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy,
embryonal/foetal development, parturition or postnatal development (see section 5.3).
18
The data on Silgard administered during pregnancy did not indicate any safety signal. However, these
data are insufficient to recommend use of Silgard during pregnancy. Vaccination should, therefore, be
postponed until completion of pregnancy.
In breastfeeding mothers given Silgard or placebo during the vaccination period of the clinical trials
the rates of adverse reactions in the mother and the breastfed infant were comparable between the
vaccination and the placebo groups. In addition, vaccine immunogenicity was comparable among
breastfeeding mothers and women who did not breastfeed during the vaccine administration.
Therefore Silgard can be given to breastfeeding women.
No studies on the effects on the ability to drive and use machines have been performed.
In 6 clinical trials (5 placebo-controlled), individuals were administered Silgard or placebo on the day
of enrollment and approximately 2 and 6 months thereafter. Few individuals (0.2%) discontinued due
to adverse reactions. Safety was evaluated in either the entire study population (5 studies) or in a
predefined subset (one study) of the study population using vaccination report card (VRC)-aided
surveillance for 14 days after each injection of Silgard or placebo. The individuals who were
monitored using VRC-aided surveillance included 8,068 individuals (6,996 females 9 to 45 years of
age and 1,072 males 9 to 15 years of age at enrollment) who received Silgard and 5,966 individuals
who received placebo.
The following vaccine-related adverse reactions were observed among recipients of Silgard at a
frequency of at least 1.0% and also at a greater frequency than observed among placebo recipients.
They are ranked under headings of frequency using the following convention:
[Very Common (≥1/10); Common (≥1/100, <1/10); Uncommon (≥1/1,000, <1/100); Rare (≥1/10,000,
<1/1,000); Very Rare (<1/10,000), including isolated reports]
Musculoskeletal and Connective Tissue Disorders:
Common: pain in extremity.
General disorders and administration site conditions:
Very common: pyrexia.
Very common: at the injection site: erythema, pain, swelling.
Common: at the injection site: bruising, pruritus.
In addition, in clinical trials adverse reactions that were judged to be vaccine- or placebo-related by
the study investigator were observed at frequencies lower than 1%:
Respiratory, thoracic and mediastinal disorders:
Very rare: bronchospasm.
Skin and subcutaneous tissue disorder:
Rare: urticaria.
Nine cases (0.07%) of urticaria were reported in the Silgard group and 16 cases (0.14%) were seen in
the adjuvant-containing placebo group.
In the clinical studies, individuals in the Safety Population reported any new medical conditions
during the follow-up of up to 4 years. Among 13,686 individuals who received Silgard and 11,588
individuals who received placebo, there were 38 cases of non-specific arthritis/arthropathy reported,
19
24 in the Silgard group and 14 in the placebo group.
In a clinical trial of 843 healthy adolescent males and females 11-17 years of age, administration of the
first dose of Silgard concomitantly with a combined diphtheria, tetanus, pertussis [acellular,
component] and poliomyelitis [inactivated] booster vaccine showed that there was more injection-site
swelling and headache reported following concomitant administration. The differences observed were
< 10% and in the majority of subjects, the adverse events were reported as mild to moderate in
intensity.
Post Marketing Experience
Post Marketing adverse events have been spontaneously reported for Silgard and are not listed above.
Because these events were reported voluntarily from a population of uncertain size, it is not possible to
reliably estimate their frequency or to establish, for all events, a causal relationship to vaccine
exposure.
Blood and lymphatic system disorders
: idiopathic thrombocytopenic purpura, lymphadenopathy.
Immune system disorders
: hypersensitivity reactions including anaphylactic/anaphylactoid reactions.
Nervous system disorders
: Guillain-Barré syndrome, dizziness,
headache, syncope sometimes
accompanied by tonic-clonic movements.
Gastrointestinal disorders
: nausea, vomiting.
Musculoskeletal and connective tissue disorders
: arthralgia, myalgia.
General disorders and administration site conditions
: asthenia, chills, fatigue, malaise.
There have been reports of administration of higher than recommended doses of Silgard.
In general, the adverse event profile reported with overdose was comparable to recommended single
doses of Silgard.
5.
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Viral Vaccine, ATC code: J07BM01
Mechanism of Action
Silgard is an adjuvanted non-infectious recombinant quadrivalent vaccine prepared from the highly
purified virus-like particles (VLPs) of the major capsid L1 protein of HPV types 6, 11, 16 and 18. The
VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. HPV only infects
humans, but animal studies with analogous papillomaviruses suggest that the efficacy of LI VLP
vaccines is mediated by the development of a humoral immune response.
HPV 16 and HPV 18 are estimated to be responsible for approximately 70% of cervical cancers; 80%
of adenocarcinoma in situ (AIS); 45-70% of high-grade cervical intraepithelial neoplasia (CIN 2/3);
25% of low grade cervical intraepithelial neoplasia (CIN 1); approximately 70% of HPV related high-
grade vulvar (VIN 2/3) and vaginal (VaIN 2/3) intraepithelial neoplasia. HPV 6 and 11 are responsible
20
for approximately 90% of genital warts and 10% of low grade cervical intraepithelial neoplasia (CIN
1). CIN 3 and AIS have been accepted as immediate precursors of invasive cervical cancer.
The term "premalignant genital lesions" in section 4.1 corresponds to high-grade cervical
intraepithelial neoplasia (CIN 2/3), high-grade vulvar intraepithelial neoplasia (VIN 2/3) and high-
grade vaginal intraepithelial neoplasia (VaIN 2/3).
The indication is based on the demonstration of efficacy of Silgard in females 16 to 45 years of age
and on the demonstration of immunogenicity of Silgard in 9- to 15-year old children and adolescents.
Clinical Studies
Efficacy in women 16 through 26 years
The efficacy of Silgard in 16- through 26- year-old women was assessed in 4 placebo-controlled,
double-blind, randomized Phase II and III clinical studies including a total of 20,541 women, who
were enrolled and vaccinated without pre-screening for the presence of HPV infection.
The primary efficacy endpoints included HPV 6-, 11-, 16-, or 18-related vulvar and vaginal lesions
(genital warts, VIN, VaIN) and CIN of any grade and cervical cancers (Protocol 013, FUTURE I),
HPV 16- or 18-related CIN 2/3 and AIS and cervical cancers (Protocol 015, FUTURE II), HPV 6-, 11-
, 16-, or 18-related persistent infection and disease (Protocol 007), and HPV 16-related persistent
infection (Protocol 005).
Efficacy results are presented for the combined analysis of study protocols. The efficacy for HPV
16/18 related CIN 2/3 or AIS is based on data from protocols 005 (16-related endpoints only), 007,
013, and 015. The efficacy for all other endpoints is based on protocols 007, 013, and 015. The median
duration of follow-up for these studies was 4.0, 3.0, 3.0, and 3.0 years for Protocol 005, Protocol 007,
Protocol 013, and Protocol 015, respectively. The median duration of follow-up for the combined
protocols (005, 007, 013, and 015) was 3.6 years. Results of individual studies support the results from
the combined analysis. Silgard was efficacious against HPV disease caused by each of the four
vaccine HPV types. At end of study, individuals enrolled in the two Phase-III studies (Protocol-013
and Protocol-015), were followed for up to 4 years (median 3.7 years).
Cervical Intraepithelial Neoplasia (CIN) Grade 2/3 (moderate to high-grade dysplasia) and
adenocarcinoma in situ
(AIS) were used in the clinical trials as a surrogate marker for cervical cancer.
Efficacy in women naïve to the relevant vaccine HPV type(s)
The primary analyses of efficacy, with respect to vaccine HPV types (HPV 6, 11, 16, and 18), were
conducted in the per-protocol efficacy (PPE) population (i.e. all 3 vaccinations within 1 year of
enrollment, no major protocol deviations and naïve to the relevant HPV type(s) prior to dose 1 and
through 1 month Postdose 3 (Month 7)). Efficacy was measured starting after the Month 7 visit.
Overall, 73% of women were naïve (PCR negative and seronegative) to all 4 HPV types at enrollment.
The efficacy results for relevant endpoints analysed at 2 years post-enrollment and at end of study
(median duration of follow-up = 3.6 years) in the per-protocol population are presented in the Table 1.
In a supplemental analysis, the efficacy of Silgard was evaluated against HPV 16/18-related CIN 3 and
AIS.
21
Table 1: Analysis of efficacy of Silgard against high grade cervical lesions in the PPE population
Silgard
Placebo
%
Efficacy
at 2
years
(95%
CI)
Silgard
Placebo
%
Efficacy***
at end of
study
(95% CI)
Number of
cases
Number of
individuals*
Number of
cases
Number of
individuals*
Number of
cases
Number of
individuals*
Number of
cases
Number of
individuals*
HPV 16/18-
related CIN
2/3 or AIS
0
8487
53
8460
100.0
(92.9,
100.0)
2**
8493
112
8464
98.2
(93.5, 99.8)
HPV 16/18-
related CIN 3
0
8487
29
8460
100
(86.5,
100.0)
2**
8493
64
8464
96.9
(88.4, 99.6)
HPV 16/18-
related AIS
0
8487
6
8460
100
(14.8,
100.0)
0
8493
7
8464
100
(30.6,
100.0)
*Number of individuals with at least one follow-up visit after Month 7
**
Based on virologic evidence, the first CIN 3 case in a patient chronically infected with HPV 52 is
likely to be causally related to HPV 52. In only 1 of 11 specimens HPV 16 was found (at Month 32.5)
and was not detected in tissue excised during LEEP (Loop Electro-Excision Procedure). In the second
CIN 3 case observed in a patient infected with HPV 51 at Day 1 (in 2 of 9 specimens); HPV 16 was
detected at a Month 51 biopsy (in 1 of 9 specimens) and HPV 56 was detected in 3 of 9 specimens at
Month 52 in tissue excised during LEEP.
***Patients were followed for up to 4 years (median 3.6 years)
Note: Point estimates and confidence intervals are adjusted for person-time of follow-up.
At end of study and in the combined protocols,
the efficacy of Silgard against HPV 6-, 11-, 16-, 18-related CIN 1 was 95.9 % (95% CI: 91.4, 98.4)
the efficacy of Silgard against HPV 6-, 11-, 16-, 18-related CIN (1, 2, 3) or AIS was 96.0% (95% CI:
92.3, 98.2)
the efficacy of Silgard against HPV 6-, 11-, 16-, 18-related VIN2/3 and VaIN 2/3 was 100% (95% CI:
67.2, 100) and 100% (95% CI: 55.4, 100) respectively
the efficacy of Silgard against HPV 6-, 11-, 16-, 18-related genital warts was 99.0% (95% CI: 96.2,
99.9).
In Protocol 012 the efficacy of Silgard against the 6 month definition of persistent infection [samples
positive on two or more consecutive visits 6 months apart (±1 month) or longer] related to HPV 16
was 98.7 % (95% CI: 95.1, 99.8) and 100.0% (95% CI: 93.2, 100.0) for HPV 18 respectively, after a
follow-up of up to 4 years (mean of 3.6 years). For the 12 month definition of persistent infection,
efficacy against HPV 16 was 100.0 % (95% CI: 93.9, 100.0) and 100.0 % (95% CI: 79.9, 100.0) for
HPV 18 respectively
.
Efficacy in women with evidence of HPV 6, 11, 16, or 18 infection or disease at day 1
There was no evidence of protection from disease caused by vaccine HPV types for which women
were PCR positive at day 1. Women who were already infected with one or more vaccine-related HPV
types prior to vaccination were protected from clinical disease caused by the remaining vaccine HPV
types.
Efficacy in women with and without prior infection or disease due to HPV 6, 11, 16, or 18
The modified intention to treat (ITT) population included women regardless of baseline HPV status at
Day 1, who received at least one vaccination and in whom case counting started at 1 month Postdose
1. This population approximates to the general population of women with respect to prevalence of
HPV infection
or disease at enrollment. The results are summarised in Table 2.
22
Table 2: Efficacy of Silgard in high grade cervical lesions in the modified ITT-population including
women regardless of baseline HPV status
Silgard
Placebo
%
Efficacy**
at 2 years
(95% CI)
Silgard
Placebo
%
Efficacy**
at end of
study
(95% CI)
Number of
cases
Number of
individuals*
Number of
cases
Number of
individuals*
Number of
cases
Number of
individuals*
Number of
cases
Number of
individuals*
HPV 16- or
HPV 18-
related CIN
2/3 or AIS
122
9831
201
9896
39.0
(23.3,
51.7)
146
9836
303
9904
51.8
(41.1,
60.7)
HPV 16/18-
related CIN
3
83
9831
127
9896
34.3
(12.7,
50.8)
103
9836
191
9904
46.0
(31.0,
57.9)
HPV 16/18-
related AIS
5
9831
11
9896
54.3
(<0, 87.6)
6
9836
15
9904
60.0
(<0, 87.3)
*Number of individuals with at least one follow-up visit after 30 days after Day 1
**Percent efficacy is calculated from the combined protocols. The efficacy for HPV 16/18 related CIN
2/3 or AIS is based on data from protocols 005 (16-related endpoints only), 007, 013, and 015.
Patients were followed for up to 4 years (median 3.6 years).
Note: point estimates and confidence intervals are adjusted for person-time of follow-up.
Efficacy against HPV 6-, 11-, 16-, 18-related VIN 2/3 was 73.3% (95% CI: 40.3, 89.4), against HPV
6-, 11-, 16-, 18-related VaIN 2/3 was 85.7% (95% CI: 37.6, 98.4), and against HPV 6-, 11-, 16-, 18-
related genital warts was 80.3% (95% CI: 73.9, 85.3) in the combined protocols at end of study.
Overall 12% of the combined study population had an abnormal Pap test suggestive of CIN at Day 1.
Among women with an abnormal Pap test at Day 1 who were naïve to the relevant vaccine HPV types
at Day 1, efficacy of the vaccine remained high. Among women with an abnormal Pap test at Day 1
who were already infected with the relevant vaccine HPV types at Day 1, no vaccine efficacy was
observed.
Protection Against the Overall Burden of Cervical HPV disease in 16- Through 26-Year-Old Women
The impact of Silgard against the overall risk for cervical, HPV disease (i.e., disease caused by any
HPV type) was evaluated starting 30 days after the first dose in 17,599 individuals enrolled in the two
phase III efficacy trials (Protocols 013 and 015). Among women who were naïve to 14 common HPV
types and had a negative Pap test at Day 1, administration of Silgard reduced the incidence of CIN 2/3
or AIS caused by vaccine- or non-vaccine HPV types by 42.7% (95% CI: 23.7, 57.3) and of genital
warts by 82.8% (95% CI: 74.3, 88.8) at end of study.
In the modified ITT population, the benefit of the vaccine with respect to the overall incidence of CIN
2/3 or AIS (caused by any HPV type) and of genital warts was much lower, with a reduction of 18.4%
(95% CI: 7.0, 28.4) and 62.5% (95% CI: 54.0, 69.5), respectively, as Silgard does not impact the
course of infections or disease that are present at vaccination onset.
Impact on Definitive Cervical Therapy Procedures
The impact of Silgard on rates of Definitive Cervical Therapy Procedures regardless of causal HPV
types was evaluated in 18,150 individuals enrolled in Protocol 007, Protocols 013 and 015. In the HPV
naïve population (naïve to 14 common HPV types and had a negative Pap test at Day 1), Silgard
reduced the proportion of women who experienced a definitive cervical therapy procedure (Loop
Electro-Excision Procedure or Cold-Knife Conization) by 41.9% (95% CI: 27.7, 53.5) at end of study.
In the ITT population the corresponding reduction was 23.9% (95% CI: 15.2, 31.7).
23
Cross-protective efficacy
The efficacy of Silgard against CIN (any grade) and CIN 2/3 or AIS caused by 10 non-vaccine HPV
types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) structurally related to HPV 16 or HPV 18 was
evaluated in the combined Phase III efficacy database (N = 17,599) after a median follow-up of 3.7
years (at end of study). Efficacy against disease endpoints caused by pre-specified combinations of
non-vaccine HPV types was measured. The studies were not powered to assess efficacy against
disease caused by individual HPV types.
The primary analysis was done in type-specific populations that required women to be negative for the
type being analyzed, but who could be positive for other HPV types (96% of the overall population).
The primary time point analysis after 3 years did not reach statistical significance for all pre-specified
endpoints. The final end-of-study results for the combined incidence of CIN 2/3 or AIS in this
population after a median follow-up of 3.7 years are shown in Table 3. For composite endpoints,
statistically significant efficacy against disease was demonstrated against HPV types phylogenetically
related to HPV 16 (primarily HPV 31) whereas no statistically significant efficacy was observed for
HPV types phylogenetically related to HPV 18 (including HPV 45). For the 10 individual HPV types,
statistical significance was only reached for HPV 31.
Table 3: Results for CIN 2/3 or AIS in Type-Specific HPV-Naïve Individuals
†
(end of study resu
lts)
Naïve to ≥ 1 HPV Type
Silgard
Placebo
Composite Endpoint
cases
cases
% Efficacy
95% CI
(HPV 31/45)
‡
34
60
43.2%
12.1, 63.9
(HPV 31/33/45/52/58)
§
111
150
25.8%
4.6, 42.5
10 non-vaccine HPV
Types
║
162
211
23.0%
5.1, 37.7
HPV-16 related types
(A9 species)
111
157
29.1%
9.1, 44.9
HPV 31
23
52
55.6%
26.2, 74.1
†
HPV 33
29
36
19.1%
<0, 52.1
†
HPV 35
13
15
13.0%
<0, 61.9
†
HPV 52
44
52
14.7%
<0, 44.2
†
HPV 58
24
35
31.5%
<0, 61.0
†
HPV-18 related types
(A7 species)
34
46
25.9%
<0, 53.9
HPV 39 15 24 37.5% <0, 69.5
†
HPV 45 11 11 0.0% <0, 60.7
†
HPV 59 9 15 39.9% <0, 76.8
†
A5 species (HPV 51) 34 41 16.3% <0, 48.5
†
A6 species (HPV 56) 34 30 -13.7% <0, 32.5
†
†
The studies were not powered to assess efficacy against disease caused by individual HPV
types.
‡
Efficacy was based on reductions in HPV 31-related CIN 2/3 or AIS
§
Efficacy was based on reductions in HPV 31-, 33-, 52-, and 58-related CIN 2/3 or AIS
║
Includes assay-identified non-vaccine HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59.
Efficacy in women 24 through 45 years
The efficacy of Silgard in 24- through 45-year-old women was assessed in 1 placebo-controlled,
double-blind, randomized Phase III clinical study (Protocol 019, FUTURE III) including a total of
3,817 women, who were enrolled and vaccinated without pre-screening for the presence of HPV
infection.
24
The primary efficacy endpoints included the combined incidence of HPV 6-, 11-, 16- or 18-related and
the combined incidence of HPV 16- or HPV 18-related persistent infection (6 month definition),
genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers. The median
duration of follow-up for this study was 4.0 years.
Efficacy in women naïve to the relevant vaccine HPV type(s)
The primary analyses of efficacy were conducted in the per-protocol efficacy (PPE) population (i.e. all
3 vaccinations within 1 year of enrollment, no major protocol deviations and naïve to the relevant
HPV type(s) prior to dose 1 and through 1 month Postdose 3 (Month 7)). Efficacy was measured
starting after the Month 7 visit. Overall, 67% of individuals were naïve (PCR negative and
seronegative) to all 4 HPV types at enrollment.
The efficacy of Silgard against the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent
infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was
88.7% (95% CI: 78.1, 94.8).
The efficacy of Silgard against the combined incidence of HPV 16- or 18-related persistent infection,
genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 84.7%
(95% CI: 67.5, 93.7).
Efficacy in women with and without prior infection or disease due to HPV 6, 11, 16, or 18
The Full Analysis Set population (also known as the ITT population) included women regardless of
baseline HPV status at Day 1, who received at least one vaccination and in whom case counting
started at Day 1. This population approximates to the general population of women with respect to
prevalence of HPV infection or disease at enrollment.
The efficacy of Silgard against the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent
infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was
47.2% (95% CI: 33.5, 58.2).
The efficacy of Silgard against the combined incidence of HPV 16- or 18-related persistent infection,
genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 41.6%
(95% CI: 24.3, 55.2).
Efficacy in women (16 to 45 years) with evidence of a prior infection with a vaccine HPV type
(seropositive) that was no longer detectable at vaccination onset (PCR negative)
In post hoc analyses of individuals (who received at least one vaccination) with evidence of a prior
infection with a vaccine HPV type (seropositive) no longer detectable (PCR negative) at vaccination
onset, the efficacy of Silgard to prevent conditions due to the recurrence of the same HPV type was
100% (95% CI: 62.8, 100.0; 0 vs. 12 cases [n = 2572 from studies in young women]) against HPV 6-,
11-, 16-, and 18-related CIN 2/3, VIN 2/3, VaIN 2/3, and genital warts in women 16 to 26 years.
Efficacy was 68.2% (95% CI: 17.9, 89.5; 6 vs. 20 cases [n= 832 from studies in young and adult
women combined]) against HPV 16- and 18-related persistent infection in women 16 to 45 years.
Immunogenicity
Assays to Measure Immune Response
No minimum antibody level associated with protection has been identified for HPV vaccines.
The immunogenicity of Silgard was assessed in 20,132 (Silgard n = 10,723; placebo n = 9,409) girls
and women 9 to 26 years of age, 1,346 (Silgard n = 1,071; placebo n = 275) boys 9 to 15 years of age
and 3,819 women 24 to 45 years of age (Silgard n = 1,911, placebo n = 1,908).
25
Type-specific immunoassays, competitive Luminex-based immunoassay (cLIA), with type-specific
standards were used to assess immunogenicity to each vaccine type. This assay measures antibodies
against a single neutralizing epitope for each individual HPV type.
Immune Responses to Silgard at 1 month post dose 3
In the clinical studies in women 16 to 26 years of age,
99.8%, 99.8%, 99.8%, and 99.5% of individuals
who received Silgard became anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18-seropositive,
respectively, by 1 month Postdose 3. In the clinical study in women
24 to 45 years, 98.4%, 98.1%,
98.8%, and 97.4% of individuals who received Silgard became anti-HPV 6, anti-HPV 11, anti-HPV
16, and anti-HPV 18 seropositive, respectively, by 1 month Postdose 3. Silgard induced high anti-HPV
Geometric Mean Titres (GMTs) 1 month Postdose 3 in all age groups tested.
As expected for women 24 to 45 years of age (Protocol 019), the observed antibody titres were lower
than that seen in women 16 to 26 years.
Anti-HPV levels in placebo individuals who had cleared an HPV infection (seropositive and PCR
negative) were substantially lower than those induced by the vaccine. Furthermore, anti-HPV levels
(GMTs) in vaccinated individuals remained at or above serostatus cut-off during the long-term follow-
up of the phase III studies (see below under
Persistence of Immune Response of Silgard in Clinical
Studies
).
Bridging the Efficacy of Silgard from Young Adult Women to Young Adolescents
A clinical study (Protocol 016) compared the immunogenicity of Silgard in 10- to 15-year-old boys
and girls to those in 16- to 23-year old adolescent and young women. In the vaccine group, 99.1 to
100% became seropositive to all vaccine serotypes by 1 month Postdose 3
.
Table 4 compares the 1 month Postdose 3 anti-HPV 6, 11, 16, and 18 GMTs in 9- to 15-year-old boys
and girls with those in 16- to 26-year old young women.
Table 4: Immunogenicity bridging between 9- to 15-year-old male and female individuals and 16- to
26-year-old adult women (per-protocol population)
based on titres as measured by cLIA
9- to 15-Year-Old Males
(Protocols 016 and 018)
9- to 15-Year-Old Females
(Protocols 016 and 018)
16- to 26-Year-Old Females
(Protocols 013 and 015)
n
GMT (95% CI)
n
GMT (95% CI)
n
GMT (95% CI)
HPV 6 883
1038 (975, 1106)
915
929 (874, 987)
2631
543 (526, 560)
HPV 11 884
1387 (1299, 1481)
915
1303 (1223, 1388)
2655
762 (735, 789)
HPV 16 881
6053 (5599, 6543)
913
4909 (4548, 5300)
2570 2294 (2185, 2408)
HPV 18 886
1356 (1253, 1469)
920
1040 (965, 1120)
2796
462 (444, 480)
GMT- Geometric mean titre in mMU/ml (mMU = milli-Merck units)
Anti-HPV responses at Month 7 among 9- to 15-year-old girls and boys were non-inferior to anti-HPV
responses in 16- to 26-year-old young women for whom efficacy was established in the phase III
studies. Immunogenicity was related to age and Month 7 anti-HPV levels were significantly higher in
younger individuals below 12 years of age than in those above that age.
On the basis of this immunogenicity bridging, the efficacy of Silgard in 9- to 15-year-old girls is
inferred.
Immunogenicity and safety of Silgard have been demonstrated in 9- to 15-year-old boys. Protective
efficacy has not been evaluated in males.
Persistence of Immune Response of Silgard in Clinical Studies
26
In women 16-26 years of age, the longest follow-up of immunogenicity was in Protocol 007 where
peak anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 GMTs were observed at Month 7. The
GMTs declined through Month 24 and then stabilized until at least Month 60. The exact duration of
immunity following a 3-dose series has not been established.
In phase III studies in women 16 through 26 years,
at end of study, 90%, 95%, 98% and 60% of
individuals who received Silgard in the per-protocol immunogenicity population were anti-HPV 6,
anti-HPV 11, anti-HPV 16 and anti HPV 18 seropositive in the cLIA, respectively.
In the Phase III study in women 24 through 45 years, after a median follow-up of 4.0 years, 91.5 %,
92.0 %, 97.4 % and 47.9 % of individuals who received Silgard in the per-protocol immunogenicity
population were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the cLIA,
respectively.
In the longer term follow-up in women 16 to 45 years, individuals who were seronegative for anti-
HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 in the cLIA, at end of study, were still protected
against clinical disease.
Evidence of Anamnestic (Immune Memory) Response
Evidence of an anamnestic response was seen in vaccinated women who were seropositive to relevant
HPV type(s) prior to vaccination. In addition, a subset of vaccinated women who received a challenge
dose of Silgard 5 years after the onset of vaccination, exhibited a rapid and strong anamnestic response
that exceeded the anti-HPV GMTs observed 1 month Postdose 3.
5.2 Pharmacokinetic properties
Evaluation of pharmacokinetic studies is not required for vaccines.
5.3 Preclinical safety data
Single-dose and repeated-dose toxicity and local tolerance studies revealed no special hazards to
humans.
Silgard induced specific antibody responses against HPV types 6, 11, 16, and 18 in pregnant rats,
following one or multiple intramuscular injections. Antibodies against all four HPV types were
transferred to the offspring during gestation and possibly during lactation. There were no treatment-
related effects on developmental signs, behaviour, reproductive performance, or fertility of the
offspring.
6.
6.1 List of excipients
Sodium chloride
L-histidine
Polysorbate 80
Sodium borate
Water for injections
For adjuvant, see section 2.
6.2 Incompatibilities
27
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal
products.
6.3 Shelf life
3 years.
6.4 Special precautions for storage
Store in a refrigerator (2°C - 8°C).
Do not freeze. Keep the pre-filled syringe in the outer carton in order to protect from light.
6.5 Nature and contents of container
0.5 ml suspension in a pre-filled syringe (Type 1 glass) with plunger stopper (siliconized FluroTec-
coated bromobutyl elastomer or non-coated chlorobutyl elastomer) and tip cap (bromobutyl) with
needle guard (safety) device, without needle or with one or two needle(s) - pack size of 1, 10 or 20.
0.5 ml suspension in a pre-filled syringe (Type 1 glass) with plunger stopper (siliconized FluroTec-
coated bromobutyl elastomer or non-coated chlorobutyl elastomer) and tip cap (bromobutyl ) without
needle guard (safety) device without needle or with one or two needle(s) - pack size of 1, 10 or 20.
Not all pack sizes are marketed.
6.6 Special precautions for disposal and other handling
•
Silgard is available in a pre-filled syringe ready to use for intramuscular injection (IM),
preferably in the deltoid area of the upper arm.
•
If 2 needles of different lengths are provided in the pack, choose the appropriate needle to
ensure an IM administration depending on your patient’s size and weight.
•
Parenteral drug products should be inspected visually for particulate matter and discolouration
prior to administration. Discard the product if particulates are present or if it appears
discoloured. Any unused product or waste material should be disposed of in accordance with
local requirements.
Using the pre-filled syringe with needle guard (safety) device
The needle guard (safety) device consists of a plastic cylinder (needle guard) that, before the dose is
given, covers the syringe barrel. The needle guard covers the needle after injection to prevent needle
stick injury. When the injection is completed and the plunger is fully depressed, the plunger will
engage the activation clips. Upon release of the plunger, the plastic cylinder will rapidly move to cover
the needle. If no needle is available in the pack, use a needle not exceeding 25 mm in length to allow
the needle guard to cover the needle completely.
Warning:
Prior to completion of the injection, avoid contact with the activation clips (as indicated by
asterisks
*
in the first illustration) on the device to keep from prematurely covering the needle with the
needle guard.
Note:
Ensure that the air bubbles are removed from the syringe before injection. The labels can only
be removed after vaccine injection and when the needle guard covers the needle.
28
Shake well before use.
Remove the syringe tip cap and the needle
cap. Screw the needle onto the syringe barrel in a clockwise direction
while pressing in the 2 plastic beads to lock the needle securely onto
the syringe.
Remove the needle shield. Inject the
full dose
by slowly pushing the
plunger forward until it cannot be pushed further.
Note
: Do not release
the pressure on the plunger.
While maintaining pressure on the plunger, remove the syringe from
the patient.
Release the plunger slowly. The needle guard will rapidly move to
cover the needle.
To remove the detachable labels, rotate the plunger until the coloured
tab becomes visible. Pull on the coloured tab while continuing to rotate
the plunger as needed.
Using the pre-filled syringe without needle guard (safety) device
Shake well before use. Attach the needle by twisting in a clockwise direction until the needle fits
securely on the syringe. Administer the entire dose as per standard protocol.
7.
Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom
8.
EU/1/06/358/003
EU/1/06/358/004
EU/1/06/358/005
EU/1/06/358/006
29
EU/1/06/358/007
EU/1/06/358/008
EU/1/06/358/009
EU/1/06/358/010
EU/1/06/358/011
EU/1/06/358/012
EU/1/06/358/013
EU/1/06/358/014
EU/1/06/358/015
EU/1/06/358/016
EU/1/06/358/017
EU/1/06/358/019
EU/1/06/358/020
EU/1/06/358/021
9.
20th September 2006
Detailed information on this product is available on the website of the European Medicines Agency
http://www.ema.europa.eu
30
ANNEX II
A.
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE
SUBSTANCE(S) AND MANUFACTURING
AUTHORISATION HOLDER(S) RESPONSIBLE FOR
BATCH RELEASE
B.
CONDITIONS OF THE MARKETING AUTHORISATION
31
A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND
MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH
RELEASE
Name and address of the manufacturer(s) of the biological active substance(s)
Merck Sharp & Dohme Corp.Sumneytown Pike
P.O.Box 4
West Point
PA 19486
USA
Name and address of the manufacturer(s) responsible for batch release
Merck Sharp & Dohme B.V.
Waarderweg 39
Postbus 581
NL-2031 Haarlem
The Netherlands
The printed package leaflet of the medicinal product must state the name and address of the
manufacturer responsible for the release of the concerned batch.
B. CONDITIONS OF THE MARKETING AUTHORISATION
•
Medicinal product subject to medical prescription.
•
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND
EFFECTIVE USE OF THE MEDICINAL PRODUCT
Not aplicable.
•
OTHER CONDITIONS
Pharmacovigilance system
The MAH must ensure that the system of pharmacovigilance, as described in version 6.0 (dated
22 June 2009) presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and
functioning before and whilst the product is on the market.
Risk Management plan
The MAH commits to performing the studies and additional pharmacovigilance activities detailed in
the Pharmacovigilance Plan, as agreed in version 4 of the Risk Management Plan (RMP) presented in
Module 1.8.2. of the Marketing Authorisation Application and any subsequent updates of the RMP
agreed by the CHMP.
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the
updated RMP should be submitted at the same time as the next Periodic Safety Update Report
(PSUR). In addition, an updated RMP should be submitted:
•
When new information is received that may impact on the current Safety Specification,
Pharmacovigilance Plan or risk minimisation activities
32
•
Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being
reached
•
At the request of the European Medicines Agency
Official batch release: in accordance with Article 114 Directive 2001/83/EC as amended, the official
batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.
33
ANNEX III
LABELLING AND PACKAGE LEAFLET
34
A. LABELLING
35
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON TEXT
Silgard, suspension for injection – single dose vial, pack of 1, 10, 20
1.
Silgard, suspension for injection.
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed).
2.
STATEMENT OF ACTIVE SUBSTANCE(S)
1 dose (0.5 ml) contains:
HPV Type 6 L1 protein
20 µg
HPV Type 11 L1 protein 40 µg
HPV Type 16 L1 protein 40 µg
HPV Type 18 L1 protein 20 µg
Adsorbed on amorphous aluminium hydroxyphosphate sulphate (225 µg Al).
3.
LIST OF EXCIPIENTS
Sodium chloride, L-histidine, polysorbate 80, sodium borate, water for injections.
4.
Suspension for injection.
1 dose vial, 0.5 ml.
10 single dose vials, 0.5 ml each.
20 single dose vials, 0.5 ml each.
5.
METHOD AND ROUTE(S) OF ADMINISTRATION
Intramuscular (IM) use.
Shake well before use.
Read the package leaflet before use.
6.
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
OF THE REACH AND SIGHT OF CHILDREN
Keep out of the reach and sight of children.
7.
OTHER SPECIAL WARNING(S), IF NECESSARY
8.
EXPIRY DATE
EXP MM/YYYY
36
9.
SPECIAL STORAGE CONDITIONS
Store in a refrigerator.
Do not freeze.
Keep the vial in the outer carton in order to protect from light.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE
Merck Sharp & Dohme Ltd
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom
EU/1/06/358/001 – pack of 1
EU/1/06/358/002– pack of 10
EU/1/06/358/018– pack of 20
13. MANUFACTURER’S BATCH NUMBER
Lot
14. GENERAL CLASSIFICATION FOR SUPPLY
Medicinal product subject to medical prescription.
15. INSTRUCTIONS ON USE
16. INFORMATION IN BRAILLE
37
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
VIAL LABEL TEXT
1.
Silgard, suspension for injection.
IM use.
2.
METHOD OF ADMINISTRATION
3.
EXPIRY DATE
EXP MM/YYYY
4.
BATCH NUMBER
Lot
5.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
1 dose, 0.5 ml.
6.
OTHER
Merck Sharp & Dohme Ltd
38
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON TEXT
Silgard, suspension for injection – pre-filled syringe without needle, pack of 1, 10, 20
1.
Silgard, suspension for injection in a pre-filled syringe.
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed).
2.
STATEMENT OF ACTIVE SUBSTANCE(S)
1 dose (0.5 ml) dose contains:
HPV Type 6 L1 protein
20 µg
HPV Type 11 L1 protein 40 µg
HPV Type 16 L1 protein 40 µg
HPV Type 18 L1 protein 20 µg
Adsorbed on amorphous aluminium hydroxyphosphate sulphate (225 µg Al).
3.
LIST OF EXCIPIENTS
Sodium chloride, L-histidine, polysorbate 80, sodium borate, water for injections.
4.
Suspension for injection in a pre-filled syringe.
1 dose, 0.5 ml pre-filled syringe without needle.
10 single doses, 0.5 ml pre-filled syringes without needles.
20 single doses, 0.5 ml pre-filled syringes without needles.
5.
METHOD AND ROUTE(S) OF ADMINISTRATION
Intramuscular (IM) use.
Shake well before use.
Read the package leaflet before use.
6.
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
OF THE REACH AND SIGHT OF CHILDREN
Keep out of the reach and sight of children.
7.
OTHER SPECIAL WARNING(S), IF NECESSARY
8.
EXPIRY DATE
EXP MM/YYYY
39
9.
SPECIAL STORAGE CONDITIONS
Store in a refrigerator.
Do not freeze.
Keep the syringe in the outer carton in order to protect from light.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE
Merck Sharp & Dohme Ltd
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom
EU/1/06/358/003 – pack of 1
EU/1/06/358/004 – pack of 10
EU/1/06/358/019 – pack of 20
13. BATCH NUMBER
Lot
14. GENERAL CLASSIFICATION FOR SUPPLY
Medicinal product subject to medical prescription.
15. INSTRUCTIONS ON USE
16. INFORMATION IN BRAILLE
40
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON TEXT
Silgard, suspension for injection – pre-filled syringe with 1 needle, pack of 1, 10, 20
1.
Silgard, suspension for injection in a pre-filled syringe.
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed).
2.
STATEMENT OF ACTIVE SUBSTANCE(S)
1 dose (0.5 ml) dose contains:
HPV Type 6 L1 protein
20 µg
HPV Type 11 L1 protein 40 µg
HPV Type 16 L1 protein 40 µg
HPV Type 18 L1 protein 20 µg
Adsorbed on amorphous aluminium hydroxyphosphate sulphate (225 µg Al).
3.
LIST OF EXCIPIENTS
Sodium chloride, L-histidine, polysorbate 80, sodium borate, water for injections.
4.
Suspension for injection in a pre-filled syringe.
1 dose, 0.5 ml pre-filled syringe with 1 needle.
10 single doses, 0.5 ml pre-filled syringes with 1 needle each.
20 single doses, 0.5 ml pre-filled syringes with 1 needle each.
5.
METHOD AND ROUTE(S) OF ADMINISTRATION
Intramuscular (IM) use.
Shake well before use.
Read the package leaflet before use.
6.
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
OF THE REACH AND SIGHT OF CHILDREN
Keep out of the reach and sight of children.
7.
OTHER SPECIAL WARNING(S), IF NECESSARY
8.
EXPIRY DATE
EXP MM/YYYY
41
9.
SPECIAL STORAGE CONDITIONS
Store in a refrigerator.
Do not freeze.
Keep the syringe in the outer carton in order to protect from light.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE
Merck Sharp & Dohme Ltd
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom
EU/1/06/358/005 – pack of 1
EU/1/06/358/006 – pack of 10
EU/1/06/358/020 – pack of 20
13. BATCH NUMBER
Lot
14. GENERAL CLASSIFICATION FOR SUPPLY
Medicinal product subject to medical prescription.
15. INSTRUCTIONS ON USE
16. INFORMATION IN BRAILLE
42
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON TEXT
Silgard, suspension for injection – pre-filled syringe with 2 needles, pack of 1, 10, 20
1.
Silgard, suspension for injection in a pre-filled syringe.
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed).
2.
STATEMENT OF ACTIVE SUBSTANCE(S)
1 dose (0.5 ml) dose contains:
HPV Type 6 L1 protein
20 µg
HPV Type 11 L1 protein 40 µg
HPV Type 16 L1 protein 40 µg
HPV Type 18 L1 protein 20 µg
adsorbed on amorphous aluminium hydroxyphosphate sulphate (225 µg Al).
3.
LIST OF EXCIPIENTS
Sodium chloride, L-histidine, polysorbate 80, sodium borate, water for injections.
4.
Suspension for injection in a pre-filled syringe.
1 dose, 0.5 ml pre-filled syringe with 2 needles.
10 single doses, 0.5 ml pre-filled syringes with 2 needles each.
20 single doses, 0.5 ml pre-filled syringes with 2 needles each.
5.
METHOD AND ROUTE(S) OF ADMINISTRATION
Intramuscular (IM) use.
Shake well before use.
Read the package leaflet before use.
6.
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
OF THE REACH AND SIGHT OF CHILDREN
Keep out of the reach and sight of children.
7.
OTHER SPECIAL WARNING(S), IF NECESSARY
8.
EXPIRY DATE
EXP MM/YYYY
43
9.
SPECIAL STORAGE CONDITIONS
Store in a refrigerator.
Do not freeze.
Keep the syringe in the outer carton in order to protect from light.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE
Merck Sharp & Dohme Ltd
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom
EU/1/06/358/007– pack of 1
EU/1/06/358/008 – pack of 10
EU/1/06/358/021 – pack of 20
13. BATCH NUMBER
Lot
14. GENERAL CLASSIFICATION FOR SUPPLY
Medicinal product subject to medical prescription.
15. INSTRUCTIONS ON USE
16. INFORMATION IN BRAILLE
44
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON TEXT
Silgard, suspension for injection – pre-filled syringe with a needle guard and no needles, pack of
1, 10, 20
1.
Silgard, suspension for injection in a pre-filled syringe.
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed).
2.
STATEMENT OF ACTIVE SUBSTANCE(S)
HPV Type 11 L1 protein 40 µg
HPV Type 16 L1 protein 40 µg
HPV Type 18 L1 protein 20 µg
20 µg
Adsorbed on amorphous aluminium hydroxyphosphate sulphate (225 µg Al).
3.
LIST OF EXCIPIENTS
Sodium chloride, L-histidine, polysorbate 80, sodium borate, water for injections.
4.
Suspension for injection in a pre-filled syringe.
1 dose, 0.5 ml pre-filled syringe with a needle guard and no needles.
10 single doses, 0.5 ml pre-filled syringes with needle guards and no needles.
20 single doses, 0.5 ml pre-filled syringes with needle guards and no needles.
5.
METHOD AND ROUTE(S) OF ADMINISTRATION
Intramuscular (IM) use.
Shake well before use.
Read the package leaflet before use.
6.
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
OF THE REACH AND SIGHT OF CHILDREN
Keep out of the reach and sight of children.
7.
OTHER SPECIAL WARNING(S), IF NECESSARY
8.
EXPIRY DATE
45
1 dose (0.5 ml) contains:
HPV Type 6 L1 protein
EXP MM/YYYY
9.
SPECIAL STORAGE CONDITIONS
Store in a refrigerator.
Do not freeze.
Keep the syringe in the outer carton in order to protect from light.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE
Merck Sharp & Dohme Ltd
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom
EU/1/06/358/009– pack of 1
EU/1/06/358/010 – pack of 10
EU/1/06/358/011 – pack of 20
13. BATCH NUMBER
Lot
14. GENERAL CLASSIFICATION FOR SUPPLY
Medicinal product subject to medical prescription.
15. INSTRUCTIONS ON USE
16. INFORMATION IN BRAILLE
46
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON TEXT
Silgard, suspension for injection – pre-filled syringe with a needle guard and 1 needle, pack of 1,
10, 20
1.
Silgard, suspension for injection in a pre-filled syringe.
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed).
2.
STATEMENT OF ACTIVE SUBSTANCE(S)
HPV Type 11 L1 protein 40 µg
HPV Type 16 L1 protein 40 µg
HPV Type 18 L1 protein 20 µg
20 µg
Adsorbed on amorphous aluminium hydroxyphosphate sulphate (225 µg Al).
3.
LIST OF EXCIPIENTS
Sodium chloride, L-histidine, polysorbate 80, sodium borate, water for injections.
4.
Suspension for injection in a pre-filled syringe.
1 dose, 0.5 ml pre-filled syringe with a needle guard and 1 needle.
10 single doses, 0.5 ml pre-filled syringes with needle guards and 1 needle each.
20 single doses, 0.5 ml pre-filled syringes with needle guards and 1 needle each.
5.
METHOD AND ROUTE(S) OF ADMINISTRATION
Intramuscular (IM) use.
Shake well before use.
Read the package leaflet before use.
6.
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
OF THE REACH AND SIGHT OF CHILDREN
Keep out of the reach and sight of children.
7.
OTHER SPECIAL WARNING(S), IF NECESSARY
8.
EXPIRY DATE
47
1 dose (0.5 ml) contains:
HPV Type 6 L1 protein
EXP MM/YYYY
9.
SPECIAL STORAGE CONDITIONS
Store in a refrigerator.
Do not freeze.
Keep the syringe in the outer carton in order to protect from light.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE
Merck Sharp & Dohme Ltd
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom
EU/1/06/358/012– pack of 1
EU/1/06/358/013 – pack of 10
EU/1/06/358/014 – pack of 20
13. BATCH NUMBER
Lot
14. GENERAL CLASSIFICATION FOR SUPPLY
Medicinal product subject to medical prescription.
15. INSTRUCTIONS ON USE
16. INFORMATION IN BRAILLE
48
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON TEXT
Silgard, suspension for injection – pre-filled syringe with a needle guard and 2 needles, pack of
1, 10, 20
1.
Silgard, suspension for injection in a pre-filled syringe.
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed).
2.
STATEMENT OF ACTIVE SUBSTANCE(S)
HPV Type 11 L1 protein 40 µg
HPV Type 16 L1 protein 40 µg
HPV Type 18 L1 protein 20 µg
20 µg
Adsorbed on amorphous aluminium hydroxyphosphate sulphate (225 µg Al).
3.
LIST OF EXCIPIENTS
Sodium chloride, L-histidine, polysorbate 80, sodium borate, water for injections.
4.
Suspension for injection in a pre-filled syringe.
1 dose, 0.5 ml pre-filled syringe with a needle guard and 2 needles.
10 single doses, 0.5 ml pre-filled syringes with needle guards and 2 needles each.
20 single doses, 0.5 ml pre-filled syringes with needle guards and 2 needles each.
5.
METHOD AND ROUTE(S) OF ADMINISTRATION
Intramuscular (IM) use.
Shake well before use.
Read the package leaflet before use.
6.
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
OF THE REACH AND SIGHT OF CHILDREN
Keep out of the reach and sight of children.
7.
OTHER SPECIAL WARNING(S), IF NECESSARY
8.
EXPIRY DATE
49
1 dose (0.5 ml) contains:
HPV Type 6 L1 protein
EXP MM/YYYY
9.
SPECIAL STORAGE CONDITIONS
Store in a refrigerator.
Do not freeze.
Keep the syringe in the outer carton in order to protect from light.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE
Merck Sharp & Dohme Ltd
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom
EU/1/06/358/015– pack of 1
EU/1/06/358/016 – pack of 10
EU/1/06/358/017 – pack of 20
13. BATCH NUMBER
Lot
14. GENERAL CLASSIFICATION FOR SUPPLY
Medicinal product subject to medical prescription.
15. INSTRUCTIONS ON USE
16. INFORMATION IN BRAILLE
50
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Pre-filled syringe label text
1.
Silgard, suspension for injection in a pre-filled syringe.
IM use.
2.
METHOD OF ADMINISTRATION
3.
EXPIRY DATE
EXP MM/YYYY
4.
BATCH NUMBER
Lot
5.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
1 dose, 0.5 ml.
6.
OTHER
Merck Sharp & Dohme Ltd
51
B. PACKAGE LEAFLET
(VIAL)
52
PACKAGE LEAFLET: INFORMATION FOR THE USER
Silgard, suspension for injection
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)
Read all of this leaflet carefully before you or your child are vaccinated.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, please ask your doctor or pharmacist.
-
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
please tell your doctor or pharmacist.
In this leaflet:
1.
What Silgard is and what it is used for
3.
How to use Silgard
4.
Possible side effects
5.
How to store Silgard
6.
Further information
1. WHAT SILGARD IS AND WHAT IT IS USED FOR
Silgard is a vaccine. Vaccination with Silgard is intended to protect against diseases caused by Human
Papillomavirus (HPV) types 6, 11, 16, and 18.
These diseases include cervical cancer; pre-cancerous lesions of the female genitals (cervix, vulva and
vagina); and genital warts. HPV types 16 and 18 are responsible for approximately 70% of cervical
cancer cases and 70% of HPV-related pre-cancerous lesions of the vulva and vagina. HPV types 6 and
11 are responsible for approximately 90% of genital wart cases.
Silgard is intended to prevent these diseases. The vaccine is not used to treat HPV related diseases.
Silgard does not have any effect in females who already have a persistent infection or disease
associated with any of the HPV types in the vaccine. However, in females who are already infected
with one or more of the vaccine HPV types, Silgard can still protect against disease associated with the
other HPV types in the vaccine.
Silgard cannot cause the diseases it protects against.
Silgard produces type-specific antibodies and has been shown in clinical trials to prevent these HPV 6-
, 11-, 16-, and 18-related diseases in adult women 16-45 years of age. The vaccine also produces
antibodies in 9- to 15-year-old children and adolescents. Whether these type-specific antibodies
prevent disease in adult males has not been evaluated.
Silgard should be used in accordance with official guidelines.
2. BEFORE YOU USE SILGARD
Do not use Silgard if:
the person to be vaccinated
•
is allergic (hypersensitive) to any of the active substances or any of the other ingredients of
53
-
This vaccine has been prescribed for you or your child. Do not pass it on to others.
2.
Before you use Silgard
Silgard (listed under “other ingredients”– see section 6).
•
has developed an allergic reaction after receiving a dose of Silgard.
•
suffers from an illness with high fever. However, a mild fever or upper respiratory infection (for
example cold) itself is not a reason to delay vaccination.
Take special care with Silgard:
You should tell your doctor if the person to be vaccinated:
•
has a bleeding disorder (a disease that makes you bleed more than normal), for example
haemophilia
•
has a weakened immune system, for example due to a genetic defect or HIV infection
As with any vaccine, Silgard may not fully protect 100% of those who get the vaccine.
Silgard will not protect against every type of Human Papillomavirus. Therefore appropriate
precautions against sexually transmitted disease should continue to be used.
Silgard will not protect against other diseases that are not caused by Human Papillomavirus.
Vaccination is not a substitute for routine cervical screening
.
You should continue to follow your
doctor’s advice on cervical smear/Pap tests and preventative and protective measures.
What other important information should I know about Silgard?
The duration of protection is currently unknown. Longer term follow-up studies are ongoing to
determine whether a booster dose is needed.
Taking other medicines:
Silgard can be given with a Hepatitis B vaccine or with a combined booster vaccine containing
diphtheria (d) and tetanus (T) with either pertussis [acellular, component] (ap) and/or poliomyelitis
[inactivated] (IPV) (dTap, dT-IPV, dTap-IPV vaccines) at a separate injection site (another part of
your body, e.g. the other arm or leg) during the same visit.
Silgard may not have an optimal effect if:
•
used with medicines that suppress the immune system.
In clinical trials, oral or other contraceptives (e.g. the pill) did not reduce the protection obtained by
Silgard.
Please tell your doctor or pharmacist if the person for whom the vaccine is intended is taking or has
recently taken any other medicines, including medicines obtained without a prescription.
Pregnancy and breast-feeding:
Consult your doctor if the person to be vaccinated is pregnant, trying to become pregnant or becomes
pregnant during the course of vaccination.
Silgard may be given to women who are breast-feeding or intend to breast-feed.
Driving and using machines:
There is no information to suggest that Silgard affects your ability to drive or use machinery.
54
3.
HOW TO USE SILGARD
Silgard is given as an injection by your doctor. Silgard is intended for adolescents from 9 through 15
years of age and females 16 years of age onwards. The person to be vaccinated will receive three
doses of the vaccine.
First injection: at chosen date
Second injection: ideally 2 months after first injection
Third injection: ideally 6 months after first injection
If an alternate vaccination schedule is necessary, the second dose should be administered at least one
month after the first dose and the third dose should be administered at least 3 months after the second
dose. All three doses should be given within a 1-year period. Please speak to your doctor for more
information.
The person to be vaccinated should complete the three-dose vaccination course; otherwise the person
to be vaccinated may not be fully protected.
Silgard will be given as an injection through the skin into the muscle (preferably the muscle of the
upper arm or thigh).
The vaccine should not be mixed in the same syringe with any other vaccines and solutions.
If you forget to take Silgard:
If you miss a scheduled injection, your doctor will decide when to give the missed dose.
It is important that you follow the instructions of your doctor or nurse regarding return visits for the
follow-up doses. If you forget or are not able to go back to your doctor at the scheduled time, ask your
doctor for advice. When Silgard is given as your first dose, the following two doses to complete the 3-
dose vaccination course should also be Silgard, and not another HPV vaccine.
If you have any further questions on the use of this product, ask your doctor or pharmacist
.
4.
POSSIBLE SIDE EFFECTS
Like all vaccines and medicines, Silgard can cause side effects, although not everybody gets them.
The following side effects can be seen after the use of Silgard:
Very commonly (more than 1 in 10 patients), side effects found at the injection site include: pain,
swelling and redness. Fever was also seen.
Commonly (more than 1 in 100 patients), side effects found at the injection site include: bruising,
itching, pain in extremity.
Rarely (less than 1 in 1000 patients): hives (urticaria).
Very rarely (less than 1 in 10,000 patients), difficulty breathing (bronchospasm) has been reported.
When Silgard was given with a combined diphtheria, tetanus, pertussis [acellular, component] and
poliomyelitis [inactivated] booster vaccine during the same visit, there was more headache and
injection-site swelling.
55
Side effects that have been reported during marketed use include:
Fainting, sometimes accompanied by shaking or stiffening, has been reported. Although fainting
episodes are uncommon, patients should be observed for 15 minutes after they receive HPV vaccine.
Allergic reactions that may include difficulty breathing, wheezing (bronchospasm), hives and rash
have been reported. Some of these reactions have been severe.
As with other vaccines, side effects that have been reported during general use include: swollen glands
(neck, armpit, or groin), Guillain-Barré Syndrome (muscle weakness, abnormal sensations, tingling in
the arms, legs and upper body), dizziness and headache, nausea and vomiting, joint pain, aching
muscles, unusual tiredness or weakness, chills, generally feeling unwell, and bleeding or bruising
more easily than normal.
If any of the side effects gets serious or if you notice any side effects not listed in this leaflet, please
tell your doctor or pharmacist.
5. HOW TO STORE SILGARD
Keep this vaccine out of the reach and sight of children.
The vaccine should not be used after the expiry date which is stated on the vial label and the outer
carton (after EXP). The expiry date refers to the last day of that month.
Store in a refrigerator (2ºC - 8ºC). Do not freeze. Keep the vial in the outer carton in order to protect
from light.
Medicines should not be disposed of via wastewater or household waste. These measures will help to
protect the environment.
6.
FURTHER INFORMATION
If you have any further questions on Silgard after reading this leaflet, please ask your doctor or
pharmacist.
What Silgard contains
The active substances are: highly purified non-infectious protein for each of the Human
Papillomavirus types (6, 11, 16, and 18).
1 dose (0.5 ml) contains approximately:
Human Papillomavirus
1
Type 6 L1 protein
2,3
20 micrograms
Human Papillomavirus
1
Type 11 L1 protein
2,3
40 micrograms
Human Papillomavirus
1
Type 16 L1 protein
2,3
40 micrograms
Human Papillomavirus
1
Type 18 L1 protein
2,3
20 micrograms
1
Human Papillomavirus = HPV
2
L1 protein in the form of virus like particles produced in yeast cells (
Saccharomyces cerevisiae
CANADE 3C-5 (Strain 1895)) by recombinant DNA technology.
3
adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (225 micrograms Al).
The other ingredients in the vaccine suspension are:
56
Sodium chloride, L-histidine, polysorbate 80, sodium borate and water for injections.
What Silgard looks like and contents of the pack
1 dose of Silgard suspension for injection contains 0.5 ml.
Prior to agitation, Silgard may appear as a clear liquid with a white precipitate. After thorough
agitation, it is a white, cloudy liquid.
Silgard is available in packs of 1, 10 or 20 vials.
Not all pack sizes are marketed.
Marketing Authorisation Holder:
Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon,
Hertfordshire EN11 9BU, United Kingdom
Manufacturer:
Merck Sharp and Dohme, B.V., Waarderweg, 39, 2031 BN Haarlem, The Netherlands
For any information about this medicinal product, please contact the local representative of the
Marketing Authorisation Holder.
België/Belgique/Belgien
Merck Sharp & Dohme B.V.,
Tél/Tel: +32 (0) 2 373 42 11
MSDBelgium_info@merck.com
Luxembourg/Luxemburg
Merck Sharp & Dohme B.V.,
Tél/Tel: +32 (0) 2 373 42 11
MSDBelgium_info@merck.com
България
Мерк Шарп и Доум България ЕООД
Тел.: +359 2 819 3740
info-msdbg@merck.com
Magyarország
MSD Magyarország Kft
Tel.: + 36.1.888.5300
hungary_msd@merck.com
Česká republika
Merck Sharp & Dohme IDEA, Inc., org. sl.
Tel.: +420.233.010.111
msd_cr@merck.com
Malta
Merck Sharp & Dohme (ME) Ltd.
Tel: +357 22866700
info_cyprus@merck.com
Danmark
Merck Sharp & Dohme,
Tlf: +45 43 28 77 66
dkmail@merck.com
Nederland
Merck Sharp & Dohme B.V.
Tel: +31 (0) 23 5153153
msdbvnl@merck.com
Deutschland
MSD SHARP & DOHME GmbH,
Tel: +49 (0) 89 4561 2612
Infocenter@msd.de
Norge
MSD (Norge) AS,
Tlf: +47 32 20 73 00
msdnorge@msd.no
Eesti
Merck Sharp & Dohme OÜ
Tel: +372.613.9750
msdeesti@merck.com
Österreich
Merck Sharp & Dohme GmbH,
Tel: +43 (0) 1 26 044
msd-medizin@merck.com
Ελλάδα
ΒΙΑΝΕΞ Α.Ε.
Τηλ: +30.210.8009111
Mailbox@vianex.gr
Polska
MSD Polska Sp. z o.o.
Tel.: +48.22.549.51.00
msdpolska@merck.com
57
España
Merck Sharp & Dohme de España, S.A.,
Tel: +34 91 321 06 00
Silgard@msd.es
Portugal
Merck Sharp & Dohme, Lda,
Tel: +351 21 4465700
informacao_doente@merck.com
France
Laboratoires Merck Sharp & Dohme – Chibret
Tél: +33 (0) 1 47 54 87 00
contact@msd-france.com
România
Merck Sharp & Dohme Romania S.R.L.
Tel: + 4021 529 29 00
msdromania@merck.com
Ireland
Merck Sharp & Dohme Ireland (Human Health)
Limited,
Tel: +353 (0)1 2998771
medinfo_ireland@merck.com
Slovenija
Merck Sharp & Dohme, d.o.o.
Tel: +386.1.520.4201
msd_slovenia@merck.com
Ísland
Icepharma hf.
Sími: +354 540 8000
ISmail@merck.com
Slovenská republika
Merck Sharp & Dohme IDEA, Inc.
Tel: +421.2.58282010
msd_sk@merck.com
Italia
Merck Sharp & Dohme (Italia) S.p.A.,
Tel: +39 06 361911
doccen@merck.com
Suomi/Finland
MSD Finland Oy,
Puh/Tel: +358 (0) 9 804650
info@msd.fi
Κύπρος
Merck Sharp & Dohme (ME) Ltd.
Τηλ: +357 22866700
info_cyprus@merck.com
Sverige
Merck Sharp & Dohme (Sweden) AB,
Tel: +46 (0) 8 626 1400
medicinskinfo@merck.com
Latvija
SIA Merck Sharp & Dohme Latvija
Tel: +371.7364.224
msd_lv@merck.com.
United Kingdom
Merck Sharp and Dohme Limited,
Tel: +44 (0) 1992 467272
medinfo_uk@merck.com
Lietuva
UAB Merck Sharp & Dohme
Tel.: +370.5.2780.247
msd_lietuva@merck.com
This leaflet was last approved in:
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu
------------------------------------------------------------------------------------------------------------------------
The following information is intended for medical or healthcare professionals only:
The vaccine should be used as supplied; no dilution or reconstitution is necessary. The full
recommended dose of the vaccine should be used.
Shake well before use
. Thorough agitation immediately before administration is necessary to maintain
suspension of the vaccine.
58
Parenteral drug products should be inspected visually for particulate matter and discolouration prior to
administration. Discard the product if particulates are present or if it appears discoloured.
59
B1 PACKAGE LEAFLET
(PREFILLED SYRINGE WITH SAFETY DEVICE)
60
PACKAGE LEAFLET: INFORMATION FOR THE USER
Silgard, suspension for injection in a pre-filled syringe
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)
Read all of this leaflet carefully before you or your child are vaccinated.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, please ask your doctor or pharmacist.
-
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
please tell your doctor or pharmacist.
In this leaflet:
1.
What Silgard is and what it is used for
3.
How to use Silgard
4.
Possible side effects
5.
How to store Silgard
6.
Further information
1. WHAT SILGARD IS AND WHAT IT IS USED FOR
Silgard is a vaccine. Vaccination with Silgard is intended to protect against diseases caused by Human
Papillomavirus (HPV) types 6, 11, 16, and 18.
These diseases include cervical cancer; pre-cancerous lesions of the female genitals (cervix, vulva and
vagina); and genital warts. HPV types 16 and 18 are responsible for approximately 70% of cervical
cancer cases and 70% of HPV-related pre-cancerous lesions of the vulva and vagina. HPV types 6 and
11 are responsible for approximately 90% of genital wart cases.
Silgard is intended to prevent these diseases. The vaccine is not used to treat HPV related diseases.
Silgard does not have any effect in females who already have a persistent infection or disease
associated with any of the HPV types in the vaccine. However, in females who are already infected
with one or more of the vaccine HPV types, Silgard can still protect against disease associated with the
other HPV types in the vaccine.
Silgard cannot cause the diseases it protects against.
Silgard produces type-specific antibodies and has been shown in clinical trials to prevent these HPV 6-
, 11-, 16-, and 18-related diseases in adult women 16-45 years of age. The vaccine also produces
antibodies in 9- to 15-year-old children and adolescents. Whether these type-specific antibodies
prevent disease in adult males has not been evaluated.
Silgard should be used in accordance with official guidelines.
2. BEFORE YOU USE SILGARD
Do not use Silgard if:
the person to be vaccinated
•
is allergic (hypersensitive) to any of the active substances or any of the other ingredients of
61
-
This vaccine has been prescribed for you or your child. Do not pass it on to others.
2.
Before you use Silgard
Silgard (listed under “other ingredients”– see section 6).
•
has developed an allergic reaction after receiving a dose of Silgard.
•
suffers from an illness with high fever. However, a mild fever or upper respiratory infection (for
example cold) itself is not a reason to delay vaccination.
Take special care with Silgard:
You should tell your doctor if the person to be vaccinated:
•
has a bleeding disorder (a disease that makes you bleed more than normal), for example
haemophilia
•
has a weakened immune system, for example due to a genetic defect or HIV infection
As with any vaccine, Silgard may not fully protect 100% of those who get the vaccine.
Silgard will not protect against every type of Human Papillomavirus. Therefore appropriate
precautions against sexually transmitted disease should continue to be used.
Silgard will not protect against other diseases that are not caused by Human Papillomavirus.
Vaccination is not a substitute for routine cervical screening
.
You should continue to follow your
doctor’s advice on cervical smear/Pap tests and preventative and protective measures.
What other important information should I know about Silgard?
The duration of protection is currently unknown. Longer term follow-up studies are ongoing to
determine whether a booster dose is needed.
Taking other medicines:
Silgard can be given with a Hepatitis B vaccine or with a combined booster vaccine containing
diphtheria (d) and tetanus (T) with either pertussis [acellular, component] (ap) and/or poliomyelitis
[inactivated] (IPV) (dTap, dT-IPV, dTap-IPV vaccines) at a separate injection site (another part of
your body, e.g. the other arm or leg) during the same visit.
Silgard may not have an optimal effect if:
•
used with medicines that suppress the immune system.
In clinical trials, oral or other contraceptives (e.g. the pill) did not reduce the protection obtained by
Silgard.
Please tell your doctor or pharmacist if the person for whom the vaccine is intended is taking or has
recently taken any other medicines, including medicines obtained without a prescription.
Pregnancy and breast-feeding:
Consult your doctor if the person to be vaccinated is pregnant, trying to become pregnant or becomes
pregnant during the course of vaccination.
Silgard may be given to women who are breast-feeding or intend to breast-feed.
Driving and using machines:
There is no information to suggest that Silgard affects your ability to drive or use machinery.
62
3.
HOW TO USE SILGARD
Silgard is given as an injection by your doctor. Silgard is intended for adolescents from 9 through 15
years of age and females 16 years of age onwards. The person to be vaccinated will receive three
doses of the vaccine.
First injection: at chosen date
Second injection: ideally 2 months after first injection
Third injection: ideally 6 months after first injection
If an alternate vaccination schedule is necessary, the second dose should be administered at least one
month after the first dose and the third dose should be administered at least 3 months after the second
dose. All three doses should be given within a 1-year period. Please speak to your doctor for more
information.
The person to be vaccinated should complete the three-dose vaccination course; otherwise the person
to be vaccinated may not be fully protected.
Silgard will be given as an injection through the skin into the muscle (preferably the muscle of the
upper arm or thigh).
The vaccine should not be mixed in the same syringe with any other vaccines and solutions.
If you forget to take Silgard:
If you miss a scheduled injection, your doctor will decide when to give the missed dose.
It is important that you follow the instructions of your doctor or nurse regarding return visits for the
follow-up doses. If you forget or are not able to go back to your doctor at the scheduled time, ask your
doctor for advice. When Silgard is given as your first dose, the following two doses to complete the 3-
dose vaccination course should also be Silgard, and not another HPV vaccine.
If you have any further questions on the use of this product, ask your doctor or pharmacist
.
4.
POSSIBLE SIDE EFFECTS
Like all vaccines and medicines, Silgard can cause side effects, although not everybody gets them.
The following side effects can be seen after the use of Silgard:
Very commonly (more than 1 in 10 patients), side effects found at the injection site include: pain,
swelling and redness. Fever was also seen.
Commonly (more than 1 in 100 patients), side effects found at the injection site include: bruising,
itching, pain in extremity.
Rarely (less than 1 in 1000 patients): hives (urticaria).
Very rarely (less than 1 in 10,000 patients), difficulty breathing (bronchospasm) has been reported.
When Silgard was given with a combined diphtheria, tetanus, pertussis [acellular, component] and
poliomyelitis [inactivated] booster vaccine during the same visit, there was more headache and
injection-site swelling.
63
Side effects that have been reported during marketed use include:
Fainting, sometimes accompanied by shaking or stiffening, has been reported. Although fainting
episodes are uncommon, patients should be observed for 15 minutes after they receive HPV vaccine.
Allergic reactions that may include difficulty breathing, wheezing (bronchospasm), hives and rash
have been reported. Some of these reactions have been severe.
As with other vaccines, side effects that have been reported during general use include: swollen glands
(neck, armpit, or groin), Guillain-Barré Syndrome (muscle weakness, abnormal sensations, tingling in
the arms, legs and upper body), dizziness and headache, nausea and vomiting, joint pain, aching
muscles, unusual tiredness or weakness, chills, generally feeling unwell, and bleeding or bruising
more easily than normal.
If any of the side effects gets serious or if you notice any side effects not listed in this leaflet, please
tell your doctor or pharmacist.
5. HOW TO STORE SILGARD
Keep this vaccine out of the reach and sight of children.
The vaccine should not be used after the expiry date which is stated on the syringe label and the outer
carton (after EXP). The expiry date refers to the last day of that month.
Store in a refrigerator (2ºC - 8ºC). Do not freeze. Keep the syringe in the outer carton in order to
protect from light.
Medicines should not be disposed of via wastewater or household waste. These measures will help to
protect the environment.
6.
FURTHER INFORMATION
If you have any further questions on Silgard after reading this leaflet, please ask your doctor or
pharmacist.
What Silgard contains
The active substances are: highly purified non-infectious protein for each of the Human
Papillomavirus types (6, 11, 16, and 18).
1 dose (0.5 ml) contains approximately:
Human Papillomavirus
1
Type 6 L1 protein
2,3
20 micrograms
Human Papillomavirus
1
Type 11 L1 protein
2,3
40 micrograms
Human Papillomavirus
1
Type 16 L1 protein
2,3
40 micrograms
Human Papillomavirus
1
Type 18 L1 protein
2,3
20 micrograms
1
Human Papillomavirus = HPV
2
L1 protein in the form of virus like particles produced in yeast cells (
Saccharomyces cerevisiae
CANADE 3C-5 (Strain 1895)) by recombinant DNA technology.
3
adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (225 micrograms Al).
The other ingredients in the vaccine suspension are:
64
Sodium chloride, L-histidine, polysorbate 80, sodium borate and water for injections.
What Silgard looks like and contents of the pack
1 dose of Silgard suspension for injection contains 0.5 ml.
Prior to agitation, Silgard may appear as a clear liquid with a white precipitate. After thorough
agitation, it is a white, cloudy liquid.
Silgard is available in packs of 1, 10, or 20 pre-filled syringes with a needle guard (safety) device.
Not all pack sizes are marketed.
Marketing Authorisation Holder:
Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon,
Hertfordshire EN11 9BU, United Kingdom
Manufacturer:
Merck Sharp and Dohme, B.V., Waarderweg, 39, 2031 BN Haarlem, The Netherlands
For any information about this medicinal product, please contact the local representative of the
Marketing Authorisation Holder.
België/Belgique/Belgien
Merck Sharp & Dohme B.V.,
Tél/Tel: +32 (0) 2 373 42 11
MSDBelgium_info@merck.com
Luxembourg/Luxemburg
Merck Sharp & Dohme B.V.,
Tél/Tel: +32 (0) 2 373 42 11
MSDBelgium_info@merck.com
България
Мерк Шарп и Доум България ЕООД
Тел.: +359 2 819 3740
info-msdbg@merck.com
Magyarország
MSD Magyarország Kft
Tel.: + 36.1.888.5300
hungary_msd@merck.com
Česká republika
Merck Sharp & Dohme IDEA, Inc., org. sl.
Tel.: +420.233.010.111
msd_cr@merck.com
Malta
Merck Sharp & Dohme (ME) Ltd.
Tel: +357 22866700
info_cyprus@merck.com
Danmark
Merck Sharp & Dohme,
Tlf: +45 43 28 77 66
dkmail@merck.com
Nederland
Merck Sharp & Dohme B.V.
Tel: +31 (0) 23 5153153
msdbvnl@merck.com
Deutschland
MSD SHARP & DOHME GmbH,
Tel: +49 (0) 89 4561 2612
Infocenter@msd.de
Norge
MSD (Norge) AS,
Tlf: +47 32 20 73 00
msdnorge@msd.no
Eesti
Merck Sharp & Dohme OÜ
Tel: +372.613.9750
msdeesti@merck.com
Österreich
Merck Sharp & Dohme GmbH,
Tel: +43 (0) 1 26 044
msd-medizin@merck.com
Ελλάδα
ΒΙΑΝΕΞ Α.Ε.
Τηλ: +30.210.8009111
Mailbox@vianex.gr
Polska
MSD Polska Sp. z o.o.
Tel.: +48.22.549.51.00
msdpolska@merck.com
65
España
Merck Sharp & Dohme de España, S.A.,
Tel: +34 91 321 06 00
Silgard@msd.es
Portugal
Merck Sharp & Dohme, Lda,
Tel: +351 21 4465700
informacao_doente@merck.com
France
Laboratoires Merck Sharp & Dohme – Chibret
Tél: +33 (0) 1 47 54 87 00
contact@msd-france.com
România
Merck Sharp & Dohme Romania S.R.L.
Tel: + 4021 529 29 00
msdromania@merck.com
Ireland
Merck Sharp & Dohme Ireland (Human Health)
Limited,
Tel: +353 (0)1 2998771
medinfo_ireland@merck.com
Slovenija
Merck Sharp & Dohme, d.o.o.
Tel: +386.1.520.4201
msd_slovenia@merck.com
Ísland
Icepharma hf.
Sími: +354 540 8000
ISmail@merck.com
Slovenská republika
Merck Sharp & Dohme IDEA, Inc.
Tel: +421.2.58282010
msd_sk@merck.com
Italia
Merck Sharp & Dohme (Italia) S.p.A.,
Tel: +39 06 361911
doccen@merck.com
Suomi/Finland
MSD Finland Oy,
Puh/Tel: +358 (0) 9 804650
info@msd.fi
Κύπρος
Merck Sharp & Dohme (ME) Ltd.
Τηλ: +357 22866700
info_cyprus@merck.com
Sverige
Merck Sharp & Dohme (Sweden) AB,
Tel: +46 (0) 8 626 1400
medicinskinfo@merck.com
Latvija
SIA Merck Sharp & Dohme Latvija
Tel: +371.7364.224
msd_lv@merck.com.
United Kingdom
Merck Sharp and Dohme Limited,
Tel: +44 (0) 1992 467272
medinfo_uk@merck.com
Lietuva
UAB Merck Sharp & Dohme
Tel.: +370.5.2780.247
msd_lietuva@merck.com
This leaflet was last approved in:
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu
------------------------------------------------------------------------------------------------------------------------
The following information is intended for medical or healthcare professionals only:
•
Silgard is available in a pre-filled syringe, with needle guard (safety device) ready to use for
intramuscular injection (IM), preferably in the deltoid area of the upper arm.
•
If 2 needles of different lengths are provided in the pack, choose the appropriate needle to
ensure an IM administration depending on your patient’s size and weight.
•
Parenteral drug products should be inspected visually for particulate matter and discolouration
66
prior to administration. Discard the product if particulates are present or if it appears
discoloured. Any unused product or waste material should be disposed of in accordance with
local requirements.
The needle guard (safety) device consists of a plastic cylinder (needle guard) that, before the dose is
given, covers the syringe barrel. The needle guard covers the needle after injection to prevent needle
stick injury. When the injection is completed and the plunger is fully depressed, the plunger will
engage the activation clips. Upon release of the plunger, the plastic cylinder will rapidly move to cover
the needle. If no needle is available in the pack, use a needle not exceeding 25 mm in length to allow
the needle guard to cover the needle completely.
Warning:
Prior to completion of the injection, avoid contact with the activation clips (as indicated by
asterisks
*
in the first illustration) on the device to keep from prematurely covering the needle with the
needle guard.
Note:
Ensure that the air bubbles are removed from the syringe before injection. The labels can only
be removed after vaccine injection and when the needle guard covers the needle.
Shake well before use.
Remove the syringe tip cap and the needle
cap. Screw the needle onto the syringe barrel in a clockwise direction
while pressing in the 2 plastic beads to lock the needle securely onto
the syringe.
Remove the needle shield. Inject the
full dose
by slowly pushing the
plunger forward until it cannot be pushed further.
Note
: Do not release
the pressure on the plunger.
While maintaining pressure on the plunger, remove the syringe from
the patient.
Release the plunger slowly. The needle guard will rapidly move to
cover the needle.
67
To remove the detachable labels, rotate the plunger until the coloured
tab becomes visible. Pull on the coloured tab while continuing to rotate
the plunger as needed.
68
B2 PACKAGE LEAFLET
(PREFILLED SYRINGE WITHOUT SAFETY DEVICE)
69
PACKAGE LEAFLET: INFORMATION FOR THE USER
Silgard, suspension for injection in a pre-filled syringe
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)
Read all of this leaflet carefully before you or your child are vaccinated.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, please ask your doctor or pharmacist.
-
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
please tell your doctor or pharmacist.
In this leaflet:
1.
What Silgard is and what it is used for
3.
How to use Silgard
4.
Possible side effects
5.
How to store Silgard
6.
Further information
1. WHAT SILGARD IS AND WHAT IT IS USED FOR
Silgard is a vaccine. Vaccination with Silgard is intended to protect against diseases caused by Human
Papillomavirus (HPV) types 6, 11, 16, and 18.
These diseases include cervical cancer; pre-cancerous lesions of the female genitals (cervix, vulva and
vagina); and genital warts. HPV types 16 and 18 are responsible for approximately 70% of cervical
cancer cases and 70% of HPV-related pre-cancerous lesions of the vulva and vagina. HPV types 6 and
11 are responsible for approximately 90% of genital wart cases.
Silgard is intended to prevent these diseases. The vaccine is not used to treat HPV related diseases.
Silgard does not have any effect in females who already have a persistent infection or disease
associated with any of the HPV types in the vaccine. However, in females who are already infected
with one or more of the vaccine HPV types, Silgard can still protect against disease associated with the
other HPV types in the vaccine.
Silgard cannot cause the diseases it protects against.
Silgard produces type-specific antibodies and has been shown in clinical trials to prevent these HPV 6-
, 11-, 16-, and 18-related diseases in adult women 16-45 years of age. The vaccine also produces
antibodies in 9- to 15-year-old children and adolescents. Whether these type-specific antibodies
prevent disease in adult males has not been evaluated.
Silgard should be used in accordance with official guidelines.
2. BEFORE YOU USE SILGARD
Do not use Silgard if:
the person to be vaccinated
•
is allergic (hypersensitive) to any of the active substances or any of the other ingredients of
70
-
This vaccine has been prescribed for you or your child. Do not pass it on to others.
2.
Before you use Silgard
Silgard (listed under “other ingredients”– see section 6).
•
has developed an allergic reaction after receiving a dose of Silgard.
•
suffers from an illness with high fever. However, a mild fever or upper respiratory infection (for
example cold) itself is not a reason to delay vaccination.
Take special care with Silgard:
You should tell your doctor if the person to be vaccinated:
•
has a bleeding disorder (a disease that makes you bleed more than normal), for example
haemophilia
•
has a weakened immune system, for example due to a genetic defect or HIV infection
As with any vaccine, Silgard may not fully protect 100% of those who get the vaccine.
Silgard will not protect against every type of Human Papillomavirus. Therefore appropriate
precautions against sexually transmitted disease should continue to be used.
Silgard will not protect against other diseases that are not caused by Human Papillomavirus.
Vaccination is not a substitute for routine cervical screening
.
You should continue to follow your
doctor’s advice on cervical smear/Pap tests and preventative and protective measures.
What other important information should I know about Silgard?
The duration of protection is currently unknown. Longer term follow-up studies are ongoing to
determine whether a booster dose is needed.
Taking other medicines:
Silgard can be given with a Hepatitis B vaccine or with a combined booster vaccine containing
diphtheria (d) and tetanus (T) with either pertussis [acellular, component] (ap) and/or poliomyelitis
[inactivated] (IPV) (dTap, dT-IPV, dTap-IPV vaccines) at a separate injection site (another part of
your body, e.g. the other arm or leg) during the same visit.
Silgard may not have an optimal effect if:
•
used with medicines that suppress the immune system.
In clinical trials, oral or other contraceptives (e.g. the pill) did not reduce the protection obtained by
Silgard.
Please tell your doctor or pharmacist if the person for whom the vaccine is intended is taking or has
recently taken any other medicines, including medicines obtained without a prescription.
Pregnancy and breast-feeding:
Consult your doctor if the person to be vaccinated is pregnant, trying to become pregnant or becomes
pregnant during the course of vaccination.
Silgard may be given to women who are breast-feeding or intend to breast-feed.
Driving and using machines:
There is no information to suggest that Silgard affects your ability to drive or use machinery.
71
3.
HOW TO USE SILGARD
Silgard is given as an injection by your doctor. Silgard is intended for adolescents from 9 through 15
years of age and females 16 years of age onwards. The person to be vaccinated will receive three
doses of the vaccine.
First injection: at chosen date
Second injection: ideally 2 months after first injection
Third injection: ideally 6 months after first injection
If an alternate vaccination schedule is necessary, the second dose should be administered at least one
month after the first dose and the third dose should be administered at least 3 months after the second
dose. All three doses should be given within a 1-year period. Please speak to your doctor for more
information.
The person to be vaccinated should complete the three-dose vaccination course; otherwise the person
to be vaccinated may not be fully protected.
Silgard will be given as an injection through the skin into the muscle (preferably the muscle of the
upper arm or thigh).
The vaccine should not be mixed in the same syringe with any other vaccines and solutions.
If you forget to take Silgard:
If you miss a scheduled injection, your doctor will decide when to give the missed dose.
It is important that you follow the instructions of your doctor or nurse regarding return visits for the
follow-up doses. If you forget or are not able to go back to your doctor at the scheduled time, ask your
doctor for advice. When Silgard is given as your first dose, the following two doses to complete the 3-
dose vaccination course should also be Silgard, and not another HPV vaccine.
If you have any further questions on the use of this product, ask your doctor or pharmacist
.
4.
POSSIBLE SIDE EFFECTS
Like all vaccines and medicines, Silgard can cause side effects, although not everybody gets them.
The following side effects can be seen after the use of Silgard:
Very commonly (more than 1 in 10 patients), side effects found at the injection site include: pain,
swelling and redness. Fever was also seen.
Commonly (more than 1 in 100 patients), side effects found at the injection site include: bruising,
itching, pain in extremity.
Rarely (less than 1 in 1000 patients): hives (urticaria).
Very rarely (less than 1 in 10,000 patients), difficulty breathing (bronchospasm) has been reported.
When Silgard was given with a combined diphtheria, tetanus, pertussis [acellular, component] and
poliomyelitis [inactivated] booster vaccine during the same visit, there was more headache and
injection-site swelling.
72
Side effects that have been reported during marketed use include:
Fainting, sometimes accompanied by shaking or stiffening, has been reported. Although fainting
episodes are uncommon, patients should be observed for 15 minutes after they receive HPV vaccine.
Allergic reactions that may include difficulty breathing, wheezing (bronchospasm), hives and rash
have been reported. Some of these reactions have been severe.
As with other vaccines, side effects that have been reported during general use include: swollen glands
(neck, armpit, or groin), Guillain-Barré Syndrome (muscle weakness, abnormal sensations, tingling in
the arms, legs and upper body), dizziness and headache, nausea and vomiting, joint pain, aching
muscles, unusual tiredness or weakness, chills, generally feeling unwell, and bleeding or bruising
more easily than normal.
If any of the side effects gets serious or if you notice any side effects not listed in this leaflet, please
tell your doctor or pharmacist.
5. HOW TO STORE SILGARD
Keep this vaccine out of the reach and sight of children.
The vaccine should not be used after the expiry date which is stated on the syringe label and the outer
carton (after EXP). The expiry date refers to the last day of that month.
Store in a refrigerator (2ºC - 8ºC). Do not freeze. Keep the syringe in the outer carton in order to
protect from light.
Medicines should not be disposed of via wastewater or household waste. These measures will help to
protect the environment.
6.
FURTHER INFORMATION
If you have any further questions on Silgard after reading this leaflet, please ask your doctor or
pharmacist.
What Silgard contains
The active substances are: highly purified non-infectious protein for each of the Human
Papillomavirus types (6, 11, 16, and 18).
1 dose (0.5 ml) contains approximately:
Human Papillomavirus
1
Type 6 L1 protein
2,3
20 micrograms
Human Papillomavirus
1
Type 11 L1 protein
2,3
40 micrograms
Human Papillomavirus
1
Type 16 L1 protein
2,3
40 micrograms
Human Papillomavirus
1
Type 18 L1 protein
2,3
20 micrograms
1
Human Papillomavirus = HPV
2
L1 protein in the form of virus like particles produced in yeast cells (
Saccharomyces cerevisiae
CANADE 3C-5 (Strain 1895)) by recombinant DNA technology.
3
adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (225 micrograms Al).
The other ingredients in the vaccine suspension are:
73
Sodium chloride, L-histidine, polysorbate 80, sodium borate and water for injections.
What Silgard looks like and contents of the pack
1 dose of Silgard suspension for injection contains 0.5 ml.
Prior to agitation, Silgard may appear as a clear liquid with a white precipitate. After thorough
agitation, it is a white, cloudy liquid.
Silgard is available in packs of 1, 10 or 20 pre-filled syringes.
Not all pack sizes are marketed.
Marketing Authorisation Holder:
Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon,
Hertfordshire EN11 9BU, United Kingdom
Manufacturer:
Merck Sharp and Dohme, B.V., Waarderweg, 39, 2031 BN Haarlem, The Netherlands
For any information about this medicinal product, please contact the local representative of the
Marketing Authorisation Holder.
België/Belgique/Belgien
Merck Sharp & Dohme B.V.,
Tél/Tel: +32 (0) 2 373 42 11
MSDBelgium_info@merck.com
Luxembourg/Luxemburg
Merck Sharp & Dohme B.V.,
Tél/Tel: +32 (0) 2 373 42 11
MSDBelgium_info@merck.com
България
Мерк Шарп и Доум България ЕООД
Тел.: +359 2 819 3740
info-msdbg@merck.com
Magyarország
MSD Magyarország Kft
Tel.: + 36.1.888.5300
hungary_msd@merck.com
Česká republika
Merck Sharp & Dohme IDEA, Inc., org. sl.
Tel.: +420.233.010.111
msd_cr@merck.com
Malta
Merck Sharp & Dohme (ME) Ltd.
Tel: +357 22866700
info_cyprus@merck.com
Danmark
Merck Sharp & Dohme,
Tlf: +45 43 28 77 66
dkmail@merck.com
Nederland
Merck Sharp & Dohme B.V.
Tel: +31 (0) 23 5153153
msdbvnl@merck.com
Deutschland
MSD SHARP & DOHME GmbH,
Tel: +49 (0) 89 4561 2612
Infocenter@msd.de
Norge
MSD (Norge) AS,
Tlf: +47 32 20 73 00
msdnorge@msd.no
Eesti
Merck Sharp & Dohme OÜ
Tel: +372.613.9750
msdeesti@merck.com
Österreich
Merck Sharp & Dohme GmbH,
Tel: +43 (0) 1 26 044
msd-medizin@merck.com
Ελλάδα
ΒΙΑΝΕΞ Α.Ε.
Τηλ: +30.210.8009111
Mailbox@vianex.gr
Polska
MSD Polska Sp. z o.o.
Tel.: +48.22.549.51.00
msdpolska@merck.com
74
España
Merck Sharp & Dohme de España, S.A.,
Tel: +34 91 321 06 00
Silgard@msd.es
Portugal
Merck Sharp & Dohme, Lda,
Tel: +351 21 4465700
informacao_doente@merck.com
France
Laboratoires Merck Sharp & Dohme – Chibret
Tél: +33 (0) 1 47 54 87 00
contact@msd-france.com
România
Merck Sharp & Dohme Romania S.R.L.
Tel: + 4021 529 29 00
msdromania@merck.com
Ireland
Merck Sharp & Dohme Ireland (Human Health)
Limited,
Tel: +353 (0)1 2998771
medinfo_ireland@merck.com
Slovenija
Merck Sharp & Dohme, d.o.o.
Tel: +386.1.520.4201
msd_slovenia@merck.com
Ísland
Icepharma hf.
Sími: +354 540 8000
ISmail@merck.com
Slovenská republika
Merck Sharp & Dohme IDEA, Inc.
Tel: +421.2.58282010
msd_sk@merck.com
Italia
Merck Sharp & Dohme (Italia) S.p.A.,
Tel: +39 06 361911
doccen@merck.com
Suomi/Finland
MSD Finland Oy,
Puh/Tel: +358 (0) 9 804650
info@msd.fi
Κύπρος
Merck Sharp & Dohme (ME) Ltd.
Τηλ: +357 22866700
info_cyprus@merck.com
Sverige
Merck Sharp & Dohme (Sweden) AB,
Tel: +46 (0) 8 626 1400
medicinskinfo@merck.com
Latvija
SIA Merck Sharp & Dohme Latvija
Tel: +371.7364.224
msd_lv@merck.com.
United Kingdom
Merck Sharp and Dohme Limited,
Tel: +44 (0) 1992 467272
medinfo_uk@merck.com
Lietuva
UAB Merck Sharp & Dohme
Tel.: +370.5.2780.247
msd_lietuva@merck.com
This leaflet was last approved in:
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu
------------------------------------------------------------------------------------------------------------------------
The following information is intended for medical or healthcare professionals only:
•
Silgard is available in a pre-filled syringe ready to use for intramuscular injection (IM),
preferably in the deltoid area of the upper arm.
•
If 2 needles of different lengths are provided in the pack, choose the appropriate needle to
ensure an IM administration depending on your patient’s size and weight.
75
•
Parenteral drug products should be inspected visually for particulate matter and discolouration
prior to administration. Discard the product if particulates are present or if it appears
discoloured. Any unused product or waste material should be disposed of in accordance with
local requirements.
Shake well before use. Attach the needle by twisting in a clockwise direction until the needle fits
securely on the syringe. Administer the entire dose as per standard protocol.
76
Source: European Medicines Agency
- Please bookmark this page (add it to your favorites).
- If you wish to link to this page, you can do so by referring to the URL address below this line.
https://theodora.com/drugs/eu/silgard.html
Copyright © 1995-2021 ITA all rights reserved.